Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 363.700 14.
Статті в журналах з теми "363.700 14"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "363.700 14".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Li, Pengyang, Ying Ning, Mu Li, Peng Cai, Ahmad Daniyal Siddiqui, Eric Yang Liu, Michelle Hadley, et al. "Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer." Journal of Cardiovascular Pharmacology and Therapeutics 25, no. 5 (May 13, 2020): 456–65. http://dx.doi.org/10.1177/1074248420925021.
Повний текст джерелаАнотація:
Background: Older patients with cancer are at high risk of developing venous thromboembolism (VTE) and bleeding. Aspirin may decrease VTE in the general population without significant bleeding. Here, we examined whether aspirin is associated with reduced rates of VTE in older patients with cancer. Methods and Results: Using the National Inpatient Sample 2016, we retrospectively identified a cohort of patients with cancer ≥65 years old who received aspirin and a similar cohort who did not receive aspirin (n = 31 654, each). The cohorts were matched for age, sex, race, patient demographics, insurance, hospital demographics, and 9 comorbidities (smoking, obesity, hypertension, hyperlipidemia, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, and history of deep venous thrombosis [DVT]/pulmonary embolism [PE]). Primary outcomes were discharge diagnosis of acute PE or acute DVT. Secondary outcomes were inhospital mortality, bleeding, length of hospital stay (LOS), and total hospitalization cost. The aspirin group, compared with the nonaspirin group, had a significantly lower incidence of acute PE (matched, 2.1% vs 2.6%, P < .001), acute DVT (matched, 2.3% vs 3.2%, P < .001), and inhospital mortality (matched 4.0% vs 6.5%, P < .001); shorter LOS (matched, 5.29 ± 5.01 vs 6.20 ± 6.56 days, P < .001); and lower total costs (matched, US$14 700 ± 15 031 vs US$16 363 ± 20 219, P < .001). The primary and secondary outcomes were similar before and after propensity matching. We found no increase in bleeding in the aspirin group compared to the nonaspirin group: gastrointestinal bleeding (matched, 3.8% vs 4.0%, P= .168), hematuria (matched, 3.5% vs 3.7%, P = .102), hemoptysis (matched, 0.9% vs 0.9%, P = .532), and hemorrhagic stroke (matched, 0.8% vs 0.8%, P = .443). In subgroup analyses, aspirin was associated with decreased inhospital mortality, mostly in patients with lung, colon, pancreatic, prostate, breast cancer, lymphoma, and leukemia. Conclusions: Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding.
2
Lawal, Folake Barakat, Ejiro Idiga, Omotayo Francis Fagbule, Iyanuoluwa Jesupemi Ajayi, Folakemi Amusa, Ooreoluwa Adejumo, Mary Ebelechukwu Osuh, Orighoye Tosan Temisanren, and Taiwo Akeem Lawal. "Association between self-reported oral habits and oral health related quality of life of adolescents in Ibadan, Nigeria." PLOS Global Public Health 4, no. 5 (May 23, 2024): e0003218. http://dx.doi.org/10.1371/journal.pgph.0003218.
Повний текст джерелаАнотація:
Oral habits such as nail biting, thumb/digit sucking and teeth grinding could be harmful, and may lead to teeth misalignment, anterior open bite, protruded or flared upper anterior teeth especially if they persist into adolescence. Such orofacial dysfunction may result to impairment of the Oral Health Related Quality of Life (OHRQoL) of an individual. The extent to which oral habits affect the major domains of the self-reported outcomes remains understudied especially during adolescence, a unique period of growth, where there is increased aesthetic desire, increased self-awareness, and unique social and psychological needs. The aim of this study, therefore, was to determine the prevalence of oral habits and its association with oral health related quality of life of adolescents. This cross-sectional study was conducted among 700 adolescents aged 10 to 19 years (with mean age 14.6 (±1.3) years) attending 14 secondary schools in Ibadan, Nigeria. Data were collected using a self-administered questionnaire, which assessed sociodemographic characteristics of the students, oral habits and OHRQoL with Oral Health Impact Profile 5 (OHIP-5). Data were analyzed with SPSS and p value was at <5%. Mann Whitney U statistics was used to test for associations between OHIP-5 scores and presence or absence of oral habits. Logistic regression was used for multivariate analysis. A total of 363 (51.9%; 95%CI = 48.1%–55.6%) bite their nails, 216 (30.9%; 95%CI = 27.5%–34.4%) breathe with their mouth, 122 (17.4%; 95%CI = 14.7%–20.4%) suck their lips, 89 (12.7%; 95%CI = 10.3%–15.4%) grind their teeth together and 32 (4.6%; 95%CI = 3.1%–6.7%) sucked their thumbs. A total of 403 (81.1%) adolescents who engaged in at least an oral habit reported an impairment of their OHRQoL. Painful aching in the mouth was the most frequently affected OHRQoL item reported by the adolescents who engaged in oral habits. Those who sucked their thumbs (OR = 2.3, 95%CI = 1.1–4.7, p = 0.028) and those who sucked their lips were more likely to have poorer OHRQoL (OR = 1.6, 95%CI = 1.1–2.5, p = 0.024). Oral habits were prevalent among the adolescents and affected their OHRQoL. Those who sucked their thumbs and lips were more likely to report poorer OHRQoL than those who did not.
3
Newman, Steven E., and Jesse R. Quarrels. "PINE BARK AND PEAT-BASED MEDIA INFLUENCE THE EFFECTS OF UNICONAZOLE DRENCH ON `GUTBIER V-14 GLORY' POINSETTIAS." HortScience 27, no. 6 (June 1992): 633d—633. http://dx.doi.org/10.21273/hortsci.27.6.633d.
Повний текст джерелаАнотація:
The objective of this study was to determine the influences of 8 commercial media, 4 peat-based and 4 pine bark-based, on the effects of uniconazole applied as a media drench to `Gutbier V-14 Glory' poinsettias. The peat-based media were Baccto Grower's Mix, Baccto High Porosity Professional, Baccto High Porosity Professional with Bacctite, and Baccto Rockwool Mix. The pine bark-based media were Metro 300, 360, 500, and 700. Uniconazole was applied to plants grown in each media at 5 rates (0, 2, 4, 6, and 8 mg · 15 cm por1). Uniconazole effectively reduced plant height and width, bract dry weight, and bract number in all media. Plants grown in the Metro products, however, tended to be larger than those grown in the Baccto products. Bract size and number, plant weight, width and height were greatest in Metro 360. The rockwool mix produced the smallest plants. Plants grown in the peat-based media were more sensitive to uniconazole drenches. Plants grown in Metro 360 were the least sensitive to uniconazole drenches.
4
Newman, Steven E., Jeffrey S. Tant, and Jesse R. Ouarrels. "PINE BARK-AND PEAT-BASED MEDIA INFLUENCE THE EFFECTS OF PACLOBUTRAZOL AND UNICONAZOLE DRENCH ON `GUTBIER V-14 GLORY' POINSETTIAS." HortScience 28, no. 5 (May 1993): 548a—548. http://dx.doi.org/10.21273/hortsci.28.5.548a.
Повний текст джерелаАнотація:
The objective of this study was to determine the influences of 8 commercial media, 4 peat-based and 4 pine bark-based, on the effects of paclobutrazol and uniconazole applied as a media drench to `Gutbier V-14 Glory' poinsettias. The peat-based media were Baccto Grower's Mix, Baccto High Porosity Professional, Baccto High Porosity Professional with Bacctite, and Baccto Rockwool Mix. The pine bark-based media were Metro 360, 366, 700, and 702. Paclobutrazol and uniconazole were each applied to plants grown in each media at 5 rates (0, 0.125, 0.250, 0.375, and 0.500 mg·15 cm pot-1). Paclobutrazol and uniconazole effectively reduced plant height in all media. Plants grown in the Metro products, however, tended to be larger than those grown in the Baccto products. Plants grown in the peatbased media were more sensitive to growth regulator drenches. Plants grown in Metro 360 and 366 were the least sensitive to plant growth regulator drenches compared to the Baccto media.
5
Olga, Olga, and Fatmawaty Fatmawaty. "EFIKASI RUTE VAKSIN Aeromonas hydrophila ASB-01 PADA IKAN GABUS (Ophiocephalus striatus)." Fish Scientiae 3, no. 6 (June 16, 2016): 131. http://dx.doi.org/10.20527/fs.v3i6.1143.
Повний текст джерелаАнотація:
Penelitian ini bertujuan untuk mengetahui rute pemberian vaksin A.hydrophila ASB-01 yang efektif untuk mengendalikan MAS pada ikan gabus. Efektivitas rute vaksinasi dievaluasi melalui titer antibodi, sintasan, RPS (relative percent survival) dan RWK (Rerata waktu kematian). Penelitian ini terdiri dari 5 perlakuan (vaksinasi secara rendaman (R), oral (O), injeksi intramuscular (IM), injeksi intraperitoneal (IP) dan Kontrol (PBS pH 7,0) dengan 3 ulangan. Dosis vaksinasi sebanyak 107 sel/ml. Vaksinasi booster dilakukan setelah 14 hari kemudian, dosisnya sama dengan vaksinasi awal. Selanjutnya, 14 hari berikutnya ikan ditantang dengan A.hydrophila ASB-01. Untuk memperoleh data titer antibodi dilakukan pengambilan darah pada saat sebelum divaksinasi, sesaat sebelum vaksinasi booster dan 14 hari setelah vaksinasi booster. Ikan tantang diamati selama 14 hari untuk memperoleh data sintasan, RPS dan RWK. Hasil menunjukkan bahwa semua rute pemberian vaksin dapat meningkatkan titer antibodi, akan tetapi titer antibodi tertinggi diperoleh dari ikan yang divaksinasi secara injeksi. Sintasan gabus yang divaksinasi secara IM (84,47%), IP (82,20%), R (42,27%), O (42,20%) dan kontrol (13,13 %). RPS gabus yang divaksinasi melalui rute IM (82,08%), IP (79,46%), R (33,38%), O (33,31%), sedangkan RWK gabus melalui rute IP (3,63 hari), IM (79,46 3,57 hari), R (2,46 hari), O (1,85 hari) dan kontrol (1,03 hari). Rute vaksinasi yang efektif adalah melalui injeksi.This study aims to determine the vaccine A.hydrophila ASB-01 is effective for the control of MAS on snakehead fish. Effectiveness of vaccination was evaluated through the antibody titer, survival, RPS (relative percent survival) and RWK (mean time of death). The study consisted of 5 treatments (immersion vaccination (R), oral (O), intramuscular injection (IM), intraperitoneal injection (IP) and control (PBS pH 7.0) with 3 replications. Vaccination doses were 107 cells / ml. Booster vaccination after 14 days later. Dose is equal to the initial vaccination. Furthermore, the next day 14 fish were challenged with A.hydrophila ASB-01. To obtain data on antibody titer blood draw done at the time before being vaccinated, shortly before the booster vaccination and 14 days after the booster vaccination. Challenged fish were observed for 14 days to obtain data on survival, RPS and RWK. The result showed that all these vaccines may increase the antibody titer, but the highest antibody titers obtained from fish vaccinated injection. Survival rates were vaccinated IM (84.47%), IP (82.20%), R (42.27%), O (42.20%) and controls (13.13%). RPS to IM (82.08%), IP (79.46%), R (33.38%), O (33.31%), while RWK through the IP (3.63 days), IM (79.46 3.57 days), R (2.46 days), O (1.85 days) and controls (1.03 days). Effective vaccination route is through injection.
6
Loew, E. R., W. N. McFarland, E. L. Mills, and D. Hunter. "A chromatic action spectrum for planktonic predation by juvenile yellow perch, Perca flavescens." Canadian Journal of Zoology 71, no. 2 (February 1, 1993): 384–86. http://dx.doi.org/10.1139/z93-053.
Повний текст джерелаАнотація:
The intensity of light required for juvenile yellow perch, Perca flavescens, to strike at planktonic prey was determined at 14 wavelengths, particular attention being paid to the near-ultraviolet region of the spectrum. Juvenile yellow perch are known to possess near-ultraviolet-sensitive photoreceptors, which are absent in adults. The action spectrum obtained shows three peaks: one between 640 and 700 nm, one between 490 and 525 nm, and one in the near-ultraviolet range, between 360 and 400 nm. The relative amplitude of the near-ultraviolet peak is greater than the amplitudes of the other two peaks. These results reveal that juvenile yellow perch can detect and recognize prey using only near-ultraviolet visual cues. This finding is discussed in terms of the visual ecology of juvenile and adult yellow perch.
7
Boyd, Matt, Giorgi Kvizhinadze, Adeline Kho, Graham Wilson, and Nick Wilson. "Cataract surgery for falls prevention and improving vision: modelling the health gain, health system costs and cost-effectiveness in a high-income country." Injury Prevention 26, no. 4 (June 20, 2019): 302–9. http://dx.doi.org/10.1136/injuryprev-2019-043184.
Повний текст джерелаАнотація:
AimTo estimate the health gain, health system costs and cost-effectiveness of cataract surgery when expedited as a falls prevention strategy (reducing the waiting time for surgery by 12 months) and as a routine procedure.MethodsAn established injurious falls model designed for the New Zealand (NZ) population (aged 65+ years) was adapted. Key parameters relating to cataracts were sourced from the literature and the NZ Ministry of Health. A health system perspective with discounting at 3% was used.ResultsExpedited cataract surgery for 1 year of incident cases was found to generate a total 240 quality-adjusted life years (QALYs) (95% uncertainty interval (UI) 161 to 360) at net health system costs of NZ$2.43 million (95% UI 2.02 to 2.82 million) over the remaining lifetimes of the surgery group. This intervention was cost-effective by widely accepted standards with an incremental cost-effectiveness ratio (ICER) of NZ$10 600 (US$7540) (95% UI NZ$6030 to NZ$15 700) per QALY gained. The level of cost-effectiveness did not vary greatly by sex, ethnicity and previous fall history, but was higher for the 65–69 age group compared with the oldest age group of 85–89 years (NZ$7000 vs NZ$14 200 per QALY gained). Comparing cataract surgery with no surgery, the ICER was even more favourable at NZ$4380 (95% UI 2410 to 7210) per QALY. Considering only the benefits for vision improvement and excluding the benefits of falls prevention, it was still favourable at NZ$9870 per QALY.ConclusionsExpedited cataract surgery appears very cost-effective. Routine cataract surgery is itself very cost-effective, and its value appears largely driven by the falls prevention benefits.
8
Somogyi, Anikó, Klára Rosta, and Tibor Vaszi. "Hearing impairment and tinnitus in patients with type 2 diabetes." Orvosi Hetilap 154, no. 10 (March 2013): 363–68. http://dx.doi.org/10.1556/oh.2013.29562.
Повний текст джерелаАнотація:
Introduction: Hearing impairment is one of the most frequent chronic health issue. The incidence of hearing impairment and tinnitus increases with age. Aim: The aim of the authors was to determine the prevalence of hearing impairment and tinnitus in type 2 diabetic patients and to examine the possible associations between hearing impairment and/or tinnitus and increased HbA1c levels. Methods: 103 patients with type 2 diabetes (47 men, 56 women; age, 61.6±10.3 years, mean±SD; range, 33–88 years) evaluated at the 2nd Department of Medicine, Semmelweis University were enrolled in this study and the results were compared to those obtained from 589 type 2 diabetic (253 men, 336 women; age, 55.4±11.0 years, mean±SD; range, 26–97 years) and 15 622 non-diabetic patients (7002 men, 8620 women; age, 55.1±11.1 years, mean±SD; range, 26–98 years) who participated in a comprehensive health screening programme in Hungary. Hearing impairment was determined using the Interacoustics model AS608 screening audiometer in all patient groups. Tinnitus was evaluated with questionnaire. Results: It was found that hearing impairment and/or tinnitus occurred in a very high proportion of type 2 diabetic patients evaluated at the 2nd Department of Medicine, Semmelweis University (80% of cases) as compared to type 2 diabetic (34% of cases) and non-diabetic patients (14% of cases) enrolled in the national health screening programme. There was no significant correlation between increased HbA1c levels and hearing impairment or tinnitus in type 2 diabetic patients. Conclusion: These results suggest that the prevalence of hearing impairment and tinnitus is higher and develop at an earlier age in patients with type 2 diabetes. The results indicate a high prevalence of hearing impairment and tinnitus in type 2 diabetic patients. Orv. Hetil., 2013, 154, 363–368.
9
Alan Amler, Dionatan, Fabrício Flávio Amler, Naiara Guerra, and Antonio Mendes de Oliveira-Neto. "Sulfentrazone formulations and herbicides for weed control in tobacco production systems." Revista Chapingo Serie Horticultura 30, no. 3 (July 3, 2024): 3–12. http://dx.doi.org/10.5154/r.rchsh.2024.04.005.
Повний текст джерелаАнотація:
Sulfentrazone is one of the main pre-emergent herbicides used in tobacco plantations. The objective of this work was to evaluate the selectivity and efficiency of sulfentrazone-based formulations in two tobacco production systems (conventional tillage system [CTS] and no-tillage system [NTS]). Two experiments were conducted (CTS and NTS) in a randomized block design, with seven treatments and four replications. The herbicide treatments were: T1 = Boral® 500 SC (400 g∙ha-1 of sulfentrazone), T2 = PonteiroBR® (400 g∙ha-1 of sulfentrazone), T3 = Stone® (350 + 700 g∙ha-1 of sulfentrazone and diuron, respectively), T4 = Boral® 500 SC + Gamit® 360 CS (792 g∙ha-1 of clomazone), T5 = PonteiroBR® + Gamit® 360 CS, T6 = Stone® + Gamit® 360 CS, and T7 = control (manual weeding). Phytotoxicity in tobacco plants and weed control efficiency were visually evaluated 14, 28, 42, and 56 days after application (daa) of the treatments. Emerged weed plants per m2 were counted 56 daa. Tobacco yield was evaluated by determining the yield per third of the plant (lower, middle, and upper thirds) and the total yield (sum of the yields from each third). The sulfentrazone formulations were efficient in weed control. The herbicide Stone® applied alone or mixed with Gamit® caused mild phytotoxicity in plants under NTS, but no yield losses. No significant difference was found in yield among treatments; however, the yield of the upper third of the plant was higher for plants under NTS, affecting the total yield. The sulfentrazone formulations used provided efficient weed control and selectivity to tobacco plants. The use of NTS resulted in higher yields.
10
Guo, Zhuo Tuan, Yong Guo, Di Wu, Jun Peng, Yong Bing Wang, and Sheng Li An. "Production Process Optimization of Mongolian Iron Ore Pellets for Baogang Group." Applied Mechanics and Materials 751 (April 2015): 35–39. http://dx.doi.org/10.4028/www.scientific.net/amm.751.35.
Повний текст джерелаАнотація:
Baogang Group imported large quantities of Mongolian iron ore to solve the shortage of ironmaking raw materials. But the basic parameters of Mongolian iron ore in pellets production are deficient. In this paper, orthogonal experimental method was used in the optimization of roasting production process of Mongolian iron ore pellets. The results show that when the content of Mongolian iron ore is 55%, the factors affecting the expansion rate of pellets in order of decrease is bentonite proportion, roasting temperature, roasting time and preheating temperature. For pellets containing 55% Mongolian iron ore, the optimum roasting schemes are as follows: bentonite proportion at 3.3%, roasting temperature at 700°C, roasting time at 14 minutes and preheating temperature at 1280°C. Under this roasting scheme, the expansion rate of pellets is 13.41%, and the compression strength reaches 2275N, which meets the technological requires of large blast furnace. The main phase of the Mongolian iron ore pellets is hematite, with a porosity of 25%-30%. And the content of gangue and liquid phase is relatively low, which is beneficial to the reduction process of pellets in blast furnace.
11
Medar, Shivanand S., Sindy Villacres, Shubhi Kaushik, Ruth Eisenberg, and Melvin E. Stone. "Pediatric Acute Respiratory Distress Syndrome (PARDS) in Children With Pulmonary Contusion." Journal of Intensive Care Medicine 36, no. 1 (November 11, 2019): 107–14. http://dx.doi.org/10.1177/0885066619887666.
Повний текст джерелаАнотація:
Objective: There is paucity of data about prevalence of pediatric acute respiratory distress syndrome (PARDS) in children with pulmonary contusion (PC). We intend to evaluate PC in children with chest trauma and the association between PC and PARDS. Design: Retrospective review of Institutional Trauma Registry for patients with trauma. Setting: Level 1 trauma center. Patients: Age 18 years and younger with a diagnosis of PC. Interventions: None. Measurements and Main Results: Of the 1916 children with trauma, 50 (2.6%) had PC. Patients with PC and PARDS had lower Glasgow Coma Scale (GCS) score (7 [3-15] vs 15 [15-15], P = .0003), higher Injury Severity Scale (ISS) score (29 [22-34] vs 19 [14-22], P = .004), lower oxygen saturations (96 [93-99] days vs 99 [98-100] days, P = .0009), higher FiO2 (1 [1-1] vs 0.21 [0.21-0.40], P < .0001), lower oxygen saturation/FiO2 (S/F) ratios (97 [90-99] vs 457 [280-471], P < .0001), need for invasive mechanical ventilation (IMV; 86% vs 23%, P < .0001), and mortality (28% vs 0%, P = .006) compared to those without PARDS. Forty-two percent (21/50) of patients needed IMV, of these 61% (13/21) had PARDS. Patients who needed IMV had significantly lower GCS score (8 [3-11] vs 15 [15-15], P < .0001), higher ISS score (27 [22-34] vs 18 [14-22], P = .002), longer length of stay (LOS; 7.5 [4-14] days vs 3.3 [2-5] days, P = .003), longer hospital LOS (18 [7.0-25] vs 5 [4-11], P = .008), higher PARDS rate (62% vs 7%, P < .0001), and lower S/F ratios (99 [94-190] vs 461 [353-471], P < .0001) compared to those who did not require IMV. Lower GCS score was independently associated with both PARDS and need for IMV. Conclusions: Pediatric ARDS in children with PC is independently associated with lower GCS score, and its presence significantly increased morbidity and mortality. Further larger studies are needed to explore association of lower GCS and higher injury score in children with PARDS and PC.
12
Verawati, Ni Nyoman Sri Putu. "The Effect of Gamma Ray (γ) Irradiation on Optical Absorption of Polymer Film Blend". Lensa: Jurnal Kependidikan Fisika 8, № 2 (15 грудня 2020): 48. http://dx.doi.org/10.33394/j-lkf.v8i2.3215.
Повний текст джерелаАнотація:
Polymer films have become a material for research recently because polymer films have an important role in the application of basic sciences. The polymer film has good mechanical, electrical and optical properties to be used in many applications, one of which is a polymer film that has the potential to be irradiated into a dosimeter. Therefore, modification of polymer film one of which is gamma ray irradiation is important to be further explored. This study aims to explore the effect of gamma ray irradiation on the optical absorption of polymer film blend PVA (polyvinyl alcohol) -trichloroacetid acid (TCA) -methylene blue (MB). Preparation of polymer films by chemical processes using the solvent-casting method. Each polymer film was irradiated with gamma rays with radiation doses ranging from 0 kGy to 14 kGy. Optical absorption was measured using a UV-VIS spectrophotometer with a range of wavelengths ranging from 200 nm to 700 nm. The results showed that three optical absorption peaks were formed on the polymer film PVA-TCA-MB due to gamma ray radiation at wavelengths of 360 nm, 440 nm, and 560 nm. Gamma ray radiation has an effect on optical absorption, where the optical absorption value of polymer film for the first peak (360 nm) and second peak (440 nm) decreased along with the increase in the dose of gamma ray irradiation, but for the third peak (560 nm) there was an increase in the optical absorption value along with an increase in the dose of gamma ray irradiation. The results of further studies are described in this article.
13
Drewnowska, K., and A. C. Schoolwerth. "Stimulatory effect of calcium on metabolism and its sensitivity to pH in kidney mitochondria." American Journal of Physiology-Renal Physiology 267, no. 1 (July 1, 1994): F153—F159. http://dx.doi.org/10.1152/ajprenal.1994.267.1.f153.
Повний текст джерелаАнотація:
The relationship between mitochondrial matrix free Ca2+ concentration ([Ca2+]m) and pH was evaluated by incubating isolated rat kidney mitochondria with different extramitochondrial Ca2+ concentrations ([Ca2+]e) at medium pH (pHe) 7.0 and 7.4. [Ca2+]m was monitored using the fluorescent signal from mitochondria loaded with the Ca2+ indicator fura 2. The changes in [Ca2+]m were compared with alpha-ketoglutarate dehydrogenase (alpha-KGDH) flux, measured as O2 consumption (nmol.min-1.mg protein-1) from 185 microM alpha-ketoglutarate (alpha-KG). The apparent dissociation constant of the matrix fluorescent probe for Ca2+ was determined in each experiment and was 323 +/- 45 nM (n = 14). When mitochondria were exposed to [Ca2+]e below 160 nM, [Ca2+]m was greater at pHe 7.0 than at pHe 7.4. However, above 160 nM [Ca2+]e, [Ca2+]m plateaued at pHe 7.0 but rose progressively at pHe 7.4. Increasing [Ca2+]m by consecutive additions of Ca2+ to the medium had a significantly more pronounced acceleratory effect on alpha-KG oxidation at pHe 7.0 than at pHe 7.4. Kinetic analysis of alpha-KGDH revealed a 45% decrease in the Michaelis constant (Km) for alpha-KG at pHe 7.0, but the Km was unchanged at pHe 7.4 with elevation of [Ca2+]m from 32 to 751 nM. Maximal velocity (Vmax) increased significantly at both pHe values. Half-maximal alpha-KG oxidation occurred at [Ca2+]m of 76 +/- 11 nM and 105 +/- 31 nM at pHe 7.0 and 7.4, respectively. These studies demonstrate a direct, pH-sensitive correlation between [Ca2+]e and [Ca2+]m; [Ca2+]m changed over a range that may regulate alpha-KGDH flux in intact kidney mitochondria.(ABSTRACT TRUNCATED AT 250 WORDS)
14
Bork, Jacqueline T., Surbhi Leekha, Emily L. Heil, LiCheng Zhao, Rilwan Badamas, and J. Kristie Johnson. "Rapid Testing Using the Verigene Gram-Negative Blood Culture Nucleic Acid Test in Combination with Antimicrobial Stewardship Intervention against Gram-Negative Bacteremia." Antimicrobial Agents and Chemotherapy 59, no. 3 (December 29, 2014): 1588–95. http://dx.doi.org/10.1128/aac.04259-14.
Повний текст джерелаАнотація:
ABSTRACTRapid identification of microorganisms and antimicrobial resistance is paramount for targeted treatment in serious bloodstream infections (BSI). The Verigene Gram-negative blood culture nucleic acid test (BC-GN) is a multiplex, automated molecular diagnostic test for identification of eight Gram-negative (GN) organisms and resistance markers from blood culture with a turnaround time of approximately 2 h. Clinical isolates from adult patients at the University Maryland Medical Center with GN bacteremia from 1 January 2012 to 30 June 2012 were included in this study. Blood culture bottles were spiked with clinical isolates, allowed to incubate, and processed by BC-GN. A diagnostic evaluation was performed. In addition, a theoretical evaluation of time to effective and optimal antibiotic was performed, comparing actual antibiotic administration times from chart review (“control”) to theoretical administration times based on BC-GN reporting and antimicrobial stewardship team (AST) review (“intervention”). For organisms detected by the assay, BC-GN correctly identified 95.6% (131/137), with a sensitivity of 97.1% (95% confidence interval [CI], 90.7 to 98.4%) and a specificity of 99.5% (95% CI, 98.8 to 99.8%). CTX-M and OXA resistance determinants were both detected. Allowing 12 h from Gram stain for antibiotic implementation, the intervention group had a significantly shorter duration to both effective (3.3 versus 7.0 h;P< 0.01) and optimal (23.5 versus 41.8 h;P< 0.01) antibiotic therapy. BC-GN with AST intervention can potentially decrease time to both effective and optimal antibiotic therapy in GN BSI.
15
Verstovsek, Srdan, Michael R. Savona, Ruben A. Mesa, Stephen Oh, Hua Dong, Dung Thai, and Jason Gotlib. "A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis." Blood 126, no. 23 (December 3, 2015): 2810. http://dx.doi.org/10.1182/blood.v126.23.2810.2810.
Повний текст джерелаАнотація:
Abstract Background: Simtuzumab (SIM) is a humanized monoclonal antibody that inhibits lysyl oxidase-like molecule 2 (LOXL2), an extracellular matrix enzyme that catalyzes the covalent cross-linking of collagen and is widely expressed across many fibrotic diseases. In pre-clinical models, inhibition of LOXL2 blocks fibroblast activation, which plays an important role in the development of organ fibrosis. In Phase 1 studies, SIM was well-tolerated in patients (pts) with advanced solid tumors, liver fibrosis, and idiopathic pulmonary fibrosis (IPF). A Phase 2, open-label study to determine the efficacy of SIM alone (Stage 1) and combined with ruxolitinib (rux) (Stage 2) in pts with primary myelofibrosis (PMF) and post-ET/PV MF was initiated. Methods: Eligible pts had intermediate-1, intermediate-2, or high risk disease and Eastern Cooperative Oncology Group performance status of <2. The primary endpoint was rate of clinical response as defined by a reduction in bone marrow fibrosis score following 24 weeks of treatment with SIM. Patients were randomized in a 1:1 ratio to receive 200 mg or 700 mg SIM by intravenous infusion every 2 weeks as monotherapy (Stage 1, n=24) or combined with rux (Stage 2, n=30). Patients received SIM for up to 24 weeks. Bone marrow biopsies and aspirates were performed approximately every 3 months. Bone marrow fibrosis scoring was performed and quantified at local investigator sites using the European Consensus on Grading Bone Marrow Fibrosis. Myelofibrosis symptoms were evaluated using the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and changes in hematologic parameters and splenomegaly were assessed. Results: Between 7/14/11 and 9/22/14, 54 pts were randomized and treated (200 mg SIM [n=12], 700 mg SIM [n=12], 200 mg SIM/rux [n=15], and 700 mg SIM/rux [n=15]). In Stage 1, 0 subjects (0%) in the SIM 200 mg group and 2 subjects (16.7%; 90% CI 3.0%, 43.8%) in the SIM 700 mg group showed a reduction in bone marrow fibrosis score from Baseline to Week 24. In Stage 2, 1 subject (6.7%; 90% CI 0.3%, 27.9%) in the SIM 200 mg/rux group and 2 subjects (13.3%, 90% CI 2.4%, 36.3%) in the SIM 700 mg/rux group showed a reduction in bone marrow fibrosis score from Baseline to Week 24. In an exploratory analysis, similar numbers of subjects showed increases in bone marrow fibrosis scores. SIM treatment was not associated with meaningful improvements in hematologic parameters or reductions in MPN-SAF score or spleen size. The most frequent adverse events were those commonly associated with MF, including constitutional symptoms and reductions in hematological parameters. Conclusions: SIM treatment alone or in combination with rux is safe but does not reliably reduce bone marrow fibrosis in pts with MF. The reason for reduction of marrow fibrosis in some patients and increase in others is unclear and may be sampling variability. Clinical studies of SIM in IPF and liver fibrosis are ongoing. Disclosures Savona: Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Research Funding; Astex Pharmaceuticals, Inc: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Mesa:Incyte Corporation: Research Funding; CTI Biopharma: Research Funding; Novartis Pharmaceuticals Corporation: Consultancy; Pfizer: Research Funding; Promedior: Research Funding; Genentech: Research Funding; NS Pharma: Research Funding; Gilead: Research Funding. Oh:CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. Dong:Gilead Sciences: Consultancy, Equity Ownership. Thai:Gilead Sciences: Employment, Equity Ownership. Gotlib:Allakos, Inc.: Consultancy.
16
Sun, Xiaowei, Huijiao Yan, Yujie Zhang, Xiao Wang, Dawei Qin, and Jinqian Yu. "Preparative Separation of Diterpene Lactones and Flavones from Andrographis paniculate Using Off-Line Two-Dimensional High-Speed Counter-Current Chromatography." Molecules 24, no. 3 (February 11, 2019): 620. http://dx.doi.org/10.3390/molecules24030620.
Повний текст джерелаАнотація:
Seven diterpene lactones, andrographolide (1), isoandrographolide (2), neo-andrographolide (3), 14-deoxy-11,12-didehydroandrographolide (4), 14-deoxyandrographiside (5), 14-deoxy-11,12-didehydroandrographiside (6), 3,14-dideoxyandrographolide (10), and three flavones, andrographidine C (7), andrographidine A (8), 5-hydroxy-7,8-dimethoxyflavanone (9) have been successfully and efficiently isolated from A. paniculata using an off-line two dimensional (2D) high-speed counter-current chromatography (HSCCC) method for the first time. For the first dimension HSCCC separation, petroleum ether-ethyl acetate-methanol-water 3:7:5:5 (v/v) was employed to isolate 14.4 mg of compound 1, 3.1 mg of compound 2, 7.8 mg of compound 3, and 18.0 mg of compound 4 from 200 mg of the A. paniculata extract. For the second dimension HSCCC separation, petroleum ether-ethyl acetate-methanol-water 2:8:1:9 (v/v) and 5:5:6:4 (v/v) were employed to isolate the collected fractions ranged from 55 to 79 min and the flow out fraction, respectively, which led to 5.1 mg of compound 5, 4.4 mg of compound 6, 2.4 mg of compound 7, 3.3 mg of compound 8, 4.0 mg of compound 9, 7.0 mg of compound 10. The structures of these diterpene lactones and flavones were elucidated by extensive spectroscopic methods.
17
Plauchu-Frayn, I., E. Colorado, M. G. Richer, and C. Herrera-Vázquez. "THIRTEEN YEARS OF WEATHER STATISTICS AT SAN PEDRO MARTIR OBSERVATORY." Revista Mexicana de Astronomía y Astrofísica 56, no. 2 (October 1, 2020): 295–319. http://dx.doi.org/10.22201/ia.01851101p.2020.56.02.11.
Повний текст джерелаАнотація:
We present weather statistics for thirteen years of data gathered with the meteorological stations at Observatorio Astronómico Nacional in the Sierra San Pedro Mártir (OAN-SPM) over the period 2007–2019. These weather stations include sensors that measure various climatological variables. The median values of the air temperature are 10.3° C and 7.0° C for daytime and nighttime, respectively. The relative humidity follows a seasonal variation with April-June being the driest months. The median values for the sustained wind speed are 11 and 14 km hr-1 for daytime and nighttime data, respectively. Preferred wind directions are SSW and North. Sustained winds are stronger at night and during December, January and February. The annual mean rain precipitation is 313 mm, most of which occurs during the summer season as afternoon thunderstorms.
18
Hoekstra, L. T., O. R. C. Busch, W. A. Bemelman, T. M. van Gulik, and P. J. Tanis. "Initial Experiences of Simultaneous Laparoscopic Resection of Colorectal Cancer and Liver Metastases." HPB Surgery 2012 (October 2, 2012): 1–6. http://dx.doi.org/10.1155/2012/893956.
Повний текст джерелаАнотація:
Introduction. Simultaneous resection of primary colorectal carcinoma (CRC) and synchronous liver metastases (SLMs) is subject of debate with respect to morbidity in comparison to staged resection. The aim of this study was to evaluate our initial experience with this approach. Methods. Five patients with primary CRC and a clinical diagnosis of SLM underwent combined laparoscopic colorectal and liver surgery. Patient and tumor characteristics, operative variables, and postoperative outcomes were evaluated retrospectively. Results. The primary tumor was located in the colon in two patients and in the rectum in three patients. The SLM was solitary in four patients and multiple in the remaining patient. Surgical approach was total laparoscopic (2 patients) or hand-assisted laparoscopic (3 patients). The midline umbilical or transverse suprapubic incision created for the hand port and/or extraction of the specimen varied between 5 and 10 cm. Median operation time was 303 (range 151–384) minutes with a total blood loss of 700 (range 200–850) mL. Postoperative hospital stay was 5, 5, 9, 14, and 30 days. An R0 resection was achieved in all patients. Conclusions. From this initial single-center experience, simultaneous laparoscopic colorectal and liver resection appears to be feasible in selected patients with CRC and SLM, with satisfying short-term results.
19
Spitzer, Thomas R., Megan Sykes, Nina Tolkoff Rubin, Tatsuo Kawai, Steven L. McAfee, Bimalangshu Dey, Karen Ballen, et al. "Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease." Blood 114, no. 22 (November 20, 2009): 3368. http://dx.doi.org/10.1182/blood.v114.22.3368.3368.
Повний текст джерелаАнотація:
Abstract Abstract 3368 Poster Board III-256 Specific tolerance following combined kidney and bone marrow transplantation (Kd/BMT)for patients with end stage renal disease (ESRD) with or without an underlying malignancy has been accomplished, as evidenced by prolonged normal renal function without ongoing immunosuppression (IS)and the demonstration of in vitro donor specific hyporesponsiveness (N Engl J Med 2008; 358:353-361; Am J Transplant 2006;6:2121-2133). In order to achieve potent anti-myeloma responses and induce tolerance through the induction of mixed chimerism (MC) for the renal allograft, 7 patients (median age 48 (34-55) yrs with multiple myeloma (MM) and ESRD received a combined HLA-matched Kd/BMT, with longest follow-up time of almost 11 years. An eighth pt developed cyclophosphamide (CY) cardiotoxicity on day -5 and did not receive a transplant. Preparative therapy for the transplants consisted of CY 60 mg/kg (days -5, -4) with hemodialysis 14 hrs after each CY dose, equine anti-thymocyte globulin, 15-20 mg/kg on days -1, +1, +3, and +5 and thymic irradiation (700 cGy) on day -1. Cyclosporine (CSP) was begun on day -1, with combined Kd/BMT on day 0. Nine additional donor lymphocyte infusions were given to 5 pts (5 for chimerism conversion, 4 for persistent/progressive disease (PD)). Acute (A) and chronic (C) GVHD developed in one patient following DLI for early PD, while chronic GVHD developed in two pts (one after a second stem cell transplant). Characteristics and outcomes of the 7 combined Kd/BMT recipients are as follows: # after 2nd transplant (myeloablative) from the same donor ; FDC: full donor chimerism In summary, 5 of 7 pts are alive, 4 without evidence of MM from 2.7 to 10.9 yrs post-Kd /BMT. Three pts have normal renal function without IS, while two pts have normal renal function on IS for chronic GVHD. Sustained renal allograft tolerance and prolonged anti-myeloma responses are achievable following nonmyeloablative HLA-matched kidney and BMT and the induction of mixed chimerism. This study was supported by the Immune Tolerance Network, National Institute of Allergy and Infectious Diseases. Disclosures: Off Label Use: Equine anti-thymocyte globulin: in vivo T cell depletion Cyclophosphamide:conditioning therapy for transplantation.
20
Атаджанова, Шаира, Дилором Ахмедова, Нурали Шавази та Мардон Рустамов. "СРАВНИТЕЛЬНАЯ ХАРАКТЕРИСТИКА ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ВИТАМИННО-МИНЕРАЛЬНОГО КОМПЛЕКСА «БИОФЕРРОН» И ДРУГИХ ЖЕЛЕЗОСОДЕРЖАЩИХ ПРЕПАРАТОВ У ДЕВОЧЕК-ПОДРОСТКОВ С РАЗЛИЧНОЙ СТЕПЕНЬЮ ТЯЖЕСТИ ДЕФИЦИТА ЖЕЛЕЗА". Международный журнал научной педиатрии 2, № 10 (31 жовтня 2023): 362–67. http://dx.doi.org/10.56121/2181-2926-2023-2-10-362-367.
Повний текст джерелаАнотація:
Аннотация: Задачи профилактики, диагностики и лечения ЖДА являются чрезвычайно актуальными и приоритетными для здравоохранения многих стран мира, в том числе и в Узбекистане. целью настоящей научной работы явилось проследить динамику терапевтической эффективности витаминно-минерального комплекса «биоферрон» и других железосодержащих препаратов у девочек-подростков с различной степенью тяжести дефицита железа. Материал и методы: Объектом исследования явилось 177 девочки-подростки в возрасте 12–14 лет, соответственно с ЛДЖ (45), ЖДА легкой степени (56) и средней степени тяжести (25) и контрольная группа (51). Исходным материалом для определения количества школьников города Андижана послужил списочный состав (алфавитный) учащихся в возрасте 7–14 лет (12000). Из этого числа учащихся с помощью таблицы Брэдфорда отобраны 1200 детей в возрасте 7–14 лет (10%-ная выборка). Были использованы общеклинические, инструментальные, биохимические и статистические методы обработки полученных результатов. Результаты и обсуждения: к концу периода насыщения уровень Hb статистически достоверно увеличивался во всех группах наблюдения (<0,001). прослеживается закономерность, что чем тяжелее степень тяжести ДЖ, тем и интенсивнее прибавка Hb за период насыщения организма железом. Если к концу периода насыщения у девочек с ЛДЖ при лечении Биофероном прибавка Hb составила в среднем 7,0 г/л, то этот показатель для ЖДА I и II степени составил 27,0 и 33,6 г/л (<0,001) соответственно. При назначении препарата Феррум-Лек прибавка Hb в группах ЛДЖ, ЖДА I и II степени тяжести составил соответственно 4,8, 29,1 и 36,5 г/л, а при сочетанном применении Биоферрона и Феррум-Лек соответственно 5,9, 27,7 и 35,4 г/л (р<0,01). Выводы: изолированное применение препарата «Биоферрон» более эффективно при коррекции относительно легких форм ДЖ (ЛДЖ). При I и II степенях тяжести ЖДА у девочек-подростков эффективность проводимой терапии значительно улучшается при сочетанном применении Биоферрон и Феррум-Лек, чем данные обеих препаратов, примененные в изолированном порядке.
21
Kenenbayev, S. B., S. B. Ramazanova, V. N. Gusev, E. K. Zhusupbekov, and A. T. Raiymbekova. "APPLICATION OF MINERAL FERTILIZERS BY PERIODS OF ORGANOGENESIS AND THEIR IMPACT ON BARLEY PRODUCTIVITY IN THE SOUTH-EAST OF KAZAKHSTAN." Bulletin of the Korkyt Ata Kyzylorda University 64, no. 1 (2023): 6–17. http://dx.doi.org/10.52081/bkaku.2023.v64.i1.001.
Повний текст джерелаАнотація:
В статье приведены результатыисследованийпо повышению продуктивности новых сортов ячменя за счет научно-обоснованного и своевременного применения удобрений по периодам органогенеза, с учетом фактической обеспеченности почвы элементами питания и планируемого уровня урожайности. Установлено, что внесение возрастающих норм минеральных удобрений по периодам органогенеза способствовало повышению содержанияподвижных элементов питания в почве. При этом щелочно-гидролизуемый азот увеличился на 7-19 мг/кг почвы,подвижныйфосфор на 8-14 и обменный калий на 70-120 мг/кг почвы.Улучшение питательного режимасветло-каштановой почвы способствовало усилению накопления биомассы растениями и в целомповышению урожайности зерна ярового ячменя в благоприятном 2022 году на 12,9- 39,2% , по сравнению с контролем -33,4 ц/га и озимого ячменя на 7,0 – 23,9 ц/га, при 26,9 ц/га на контроле. Окупаемость удобрений зерном ярового ячменя в засушливом 2021 году составила: у сорта Сымбат в пределах 3,3-3,8 кг/кг, у сорта Жан от 2,3 до 2,6; против нормативной окупаемости в 3,7 кг/кг
22
Colombo, Eduardo, Reinaldo F. Cooke, Alice Brandão, Jacob Wiegand, Kelsey Schubach, CiCi A. Sowers, Glenn Duff, and Vinicius N. Gouvea. "PSVII-14 Performance and health responses of feedlot cattle consuming different feed additives during a 45-day receiving period." Journal of Animal Science 98, Supplement_4 (November 3, 2020): 295–96. http://dx.doi.org/10.1093/jas/skaa278.533.
Повний текст джерелаАнотація:
Abstract This experiment compared performance and health responses of feedlot cattle consuming different feed additives during a 45-d receiving period. Angus-influenced steers (n = 256) were purchased from a commercial auction yard, and road-transported (12 h) to the experimental feedyard on d -1. Upon arrival, body weight (BW) was recorded and steers were ranked by BW into 1 or 18 drylot pens (14 or 15 steers/pen). Pens were randomly assigned to receive RAMP® from d 0 to d 45 with the inclusion of: 1) Rumensin + Tylan (Elanco Animal Health; Greenfield, IN; 360 mg and 90 mg per animal/daily, respectively; RT), 2) Rumensin + Celmanax + Certillus (Church and Dwight Co., Inc., Princeton, NJ; 18 g and 28 per animal/daily, respectively; RCC), or Celmanax + Certillus (18 g and 28 per animal/daily, respectively; CC). Feed intake during the initial 21 d of the experiment was greater (P ≤ 0.05) in CC vs. RCC and RT. No treatment effects were detected for steer BW gain and feed efficiency (P ≥ 0.41). Total incidence of steers treated for respiratory disease did not differ between treatments (77.9, 82.3, and 80.0%, respectively, P = 0.77). Removal of steers from the experiment due to extreme morbidity of mortality was greater (P = 0.02) in RT vs. CC, and intermediate for RCC (22.4, 7.0, and 12.9%, respectively). Accordingly, total liveweight per pen on d 45 was greater (P ≤ 0.05) for CC and RCC vs. RT (3.79, 3.61, and 3.20 ton, respectively). Inclusion of CC into a receiving diet improved initial feed intake compared with ionophore-containing diets, but without changing steer performance. Moreover, CC and RCC resulted in improved health responses during the 45-d receiving period compared with the traditional RT receiving diet. These results suggest that CC ingredients improved intake and immunocompetence of receiving cattle.
23
Hill, David W., Jakob L. Vingren, and Samantha D. Burdette. "Effect of plasma donation and blood donation on aerobic and anaerobic responses in exhaustive, severe-intensity exercise." Applied Physiology, Nutrition, and Metabolism 38, no. 5 (May 2013): 551–57. http://dx.doi.org/10.1139/apnm-2012-0361.
Повний текст джерелаАнотація:
The purpose of this study was to investigate the immediate and delayed effects of plasma donation and blood donation on responses in exhaustive, severe-intensity exercise. Nineteen young men and women performed exhaustive cycle ergometer tests at ∼3.3 W·kg−1 before and then 2 h, 2 days, and 7 days after withdrawal of either 8–10 mL·kg−1 (∼700 mL) of plasma (n = 10) or 1 unit (450 mL) of whole blood (n = 9). Time to exhaustion was significantly (p < 0.05) decreased after the removal of plasma (−11% after 2 h) and after the removal of blood (−19% after 2 h and −7% after 2 days). Maximal oxygen uptake ([Formula: see text]) was not affected by plasma donation, but [Formula: see text] was reduced following blood withdrawal (−15% after 2 h, −10% after 2 days, and −7% after 7 days) presumably because of effects on blood volume, total haemoglobin content, and haemoglobin concentration. The kinetics of the oygen uptake ([Formula: see text]) response was not affected by either intervention. Two measures of anaerobic capacity, postexercise blood lactate concentration, and maximal accumulated oxygen deficit were reduced (−14%, −15%, respectively) 2 h after plasma donation, but neither was affected by blood donation. Removal of plasma and removal of blood have different effects on blood constituency, on the [Formula: see text] response, and on performance. Plasma donation appears to affect exercise performance because of reduced anaerobic capacity, whereas blood donation affects performance because of lowered [Formula: see text].
24
Macari, David, Samer Kawak, Lilian Hanna, Daniel Ezekwudo, John Khoury, Harry Wasvary, and Ishmael A. Jaiyesimi. "Recurrence pattern and outcomes in T4 colon cancer: A single institution analysis." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 706. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.706.
Повний текст джерелаАнотація:
706 Background: Patients with T4 colon adenocarcinoma have an increased risk of peritoneal recurrence due to direct seeding malignant cells. It has been theorized that adjuvant chemotherapy may not sterilize the peritoneal surface due to inadequate intraperitoneal concentration. We seek to further define the metastatic pattern, predictors of recurrence, and efficacy of adjuvant treatment in T4 colon cancer. Methods: We reviewed records of 181 adults [median age 71 (22-97)] with T4 N0-3 colon adenocarcinoma at Beaumont Hospital, Michigan from May 2005 –Nov 2015. Baseline factors and data on follow up, metastasis, and survival were collected and analyzed. Results: Overall recurrence rates for N0, N1, and N2 were 27/85 (32%), 17/50 (34%), and 29/46 (63%) (p = 0.001). Locoregional recurrence (LR) rates for N0, N1, and N2 were 21/85 (24.7%), 14/50 (28%), and 21/46 (45.7%) (p = 0.014). Multivariate analysis for distant recurrence was significant only for positive nodes with hazard ratio (HR) 3.3, 95% confidence interval (CI) 1.1-9.9. Multivariate analysis for increased risk of LR was significant for the following variables: perforation (HR 2.7, 95% CI 1.2 – 6.2), lymphovascular invasion (HR 2.7, 95% CI 1.1 – 6.7), positive nodes (HR 2.8, 95% CI 1.2 – 6.9), and positive margins (HR 5.0, 95% CI 2.1 – 12.1). Adjuvant chemotherapy did not decrease risk of LR (HR 0.6, 95% CI 0.3-1.2) or distant recurrence (HR 0.9, 95% CI 0.3-2.8). Multivariate analysis for overall survival revealed the following to be associated with increased risk of mortality: signet ring (HR 2.5, 95% CI 1.2-5.8), positive nodes (HR 2.3, 95% CI 1.2-4.4), positive margin (HR 2.8, 95% CI 1.4-5.8). Adjuvant chemotherapy was not associated with improved survival (HR 0.8, 95% CI 0.4-1.7). Recurrence was strongly associated with colon cancer-specific death with a p < 0.001. Conclusions: Adjuvant chemotherapy is standard of care for most T4 colon cancer patients, however, this data suggests there is no improvement in survival or other significant outcomes. We have identified several risk factors which predict increased risk of LR. This data suggests LR is frequent and not affected by systemic chemotherapy. Prospective trials are needed to reduce the substantial risk of LR in T4 colon cancer.
25
Alfayez, Mansour, Iman Abou Dalle, Guillaume Abou Richard-Carpentier, Daewoo Pak, Jing Ning, Sherry A. Pierce, Koji Sasaki, et al. "Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 7002. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.7002.
Повний текст джерелаАнотація:
7002 Background: Smoking increases the relative risk of AML by 40% and 25% in active and former smokers, respectively, compared with non-smokers (Fircanis et al., 2014). While the relationship of smoking with AML development is recognized, whether smoking impacts underling AML biology and clinical outcome remains ill-defined. Methods: Newly diagnosed, treatment naïve AML pts seen at MDACC between 2012 and 2017 with available smoking history were evaluated, along with baseline parameters, co-occurring mutations, cytogenetics and clinical outcome. Results: We identified 858 pts [486 (57%) male; median age 67 yrs (14-97)], representing 535 (62%) treatment naïve and 323 (38%) salvage pts. Smoking status was recorded as smokers (active = 39 pt, former = 380 pt), versus never smoker (439 pt). In tx naïve group, smoking is associated with lower remission rates (OR 0.63, 95% CI 0.43-0.94, p = 0.02) and inferior OS (HR = 1.6, 95% CI 1.27-2.02, p < 0.001). Smoking status was not significant in multivariate analysis including AML biologic characteristics and ELN 2017 risk stratification. Therefore we postulated that worse OS may be driven by smoking associated AML biology rather than smoking associated comorbidities. Indeed, in univariate analysis smoking was associated with poor ELN risk (p = 0.015), complex karyotype (p = 0.0002), and TP53 mutation (p = 0.0235) while negatively associated with NPM1 (p = 0.018), FLT3-ITD (p = 0.032) and GATA2 (p = 0.0497). Age was a significant cofounder between smokers vs non-smoker ( < 0.0001). After controlling for age, significance was retained for ELN risk, complex karyotype and GATA2 at p = 0.0454, p = 0.0006, p = 0.048 respectively, while significance was lost for NPM1 (p = 0.079), FLT3-ITD (p = 0.1) and TP53 (p = 0.084). In analysis of young pts ( < 60 yr), smoking is positively associated with complex karyotype (p = 0.0042) and TP53 (p = 0.0289), and negatively associated with RUNX1 (p = 0.0143) and IDH2 (p = 0.0357). Conclusions: We report the largest analysis of smoking status and impact on molecular, cytogenetics, and AML clinical outcomes. Smoking history is associated with poorer risk molecular and cytogenetics, lower response rate and shorter survival in treatment naïve patients.
26
Paulino Pereira, Nuno Rui, Stein J. Janssen, Nicky Stoop, Stefan Hartveldt, Yen-Lin E. Chen, Thomas F. DeLaney, Francis J. Hornicek, and Joseph H. Schwab. "Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma." Global Spine Journal 9, no. 7 (February 18, 2019): 743–53. http://dx.doi.org/10.1177/2192568219830330.
Повний текст джерелаАнотація:
Study Design: Retrospective cohort study. Objectives: (1) To assess patient-reported outcomes—physical function, pain, and quality of life—in patients who underwent resection of a mobile spine chondrosarcoma. (2) To assess complications (90 days), readmissions, reoperations, oncological outcomes, and neurologic status. Methods: Thirty-three patients with spinal conventional chondrosarcoma resection between 1984 and 2014 at one hospital were included. The primary outcome measures were—minimally 6 months after surgery—the EuroQol 5 Dimensions (EQ5D), PROMIS–Physical Function, PROMIS–Pain Intensity, and Oswestry (ODI) Disability Index, or Neck (NDI) Disability established in 14 out of 20 alive (70.0%) patients. Complications, readmission, reoperations, oncological outcomes, and neurological status were reported for the complete cohort of 33 patients. Results: After spine chondrosarcoma resection, patients (n = 14) reported worse physical function (median 43, range 22-61, P = .026), worse quality of life (median EQ5D 0.70, range 0.04-1, P = .022), and comparable pain intensity (median 47, range 31-56, P = .362) when compared with US general population values. The median NDI/ODI was 25 (range 0-72) indicating mild to moderate disability. Patients undergoing reoperation had worse patient-reported outcomes than those who did not. Eighteen (55.5%) out of 33 patients suffered complications (90 days), 14 (42.4%) had unplanned readmission, and 13 (39.4%) underwent reoperation. Intralesional resection was associated with increased readmission, reoperation, and recurrence rate. Conclusions: Chondrosarcoma affects quality of life and physical function and its treatment frequently results in complications and reoperations. Our findings can be used to inform future patients about expected outcomes.
27
Uddin, M. Minhaz, Tasmia Islam, M. Sharif Hossain, M. Harun Are Rashid, Barshan Bose, and M. Sohel Rana. "Outcome of closed intramedullary fixation of femoral shaft fracture by titanium elastic nail in children." International Journal of Research in Orthopaedics 11, no. 2 (February 25, 2025): 264–68. https://doi.org/10.18203/issn.2455-4510.intjresorthop20250448.
Повний текст джерелаАнотація:
Background: Femoral shaft fractures are most common fractures in paediatric orthopaedic age group. The best treatment between six to fourteen years of age is a matter of debate. Titanium flexible elastic intramedullary nailing has become a well-accepted method of treatment of paediatric femoral shaft fractures. This study aims to evaluate the functional outcome of treatment of femoral shaft fracture by closed intramedullary titanium elastic nail (TEN) in children age between 6 to 14 years. Methods: This prospective observational study was conducted over a period of two years from July 2017 to June 2019. Thirty children (23 boys, 7 girls) aged 6-14 years with femoral diaphyseal fractures were stabilized with retrograde titanium elastic nail. The results were evaluated by using Flynn’s TEN scoring criteria. Two nails were used in each fracture. Results: Mean age was 11.1±1.8 years with male female ratio 3.3:1. Male patients were predominant in this study. Type of fracture were observed that 10(33.3%) cases were oblique, 18 (60.0%) cases were transverse and spiral 2 (6.7%). Radiological union in all cases were achieved in a mean time of 9.6±1.9 weeks. Objective evaluation showed that 21 (70.0%) patients had knee flexion >130°, 7 (23.3%) had restricted motion of 120–130°, and 2 (6.7%) had a range of 100–120°. The results were excellent in 23 patients (76.7%), satisfactory in 7 patients (23.3%) and there was no poor result. Conclusions: TEN fixation of paediatric femoral shaft fractures is an excellent method of treatment in children aged 6-14 years.
28
Faber, Jens, Carsten Kirkegaard, Bo Jørgensen, and Jørgen Kludt. "The hidden, nonexchangeable pool of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine in man: does it exist?" Acta Endocrinologica 120, no. 5 (May 1989): 667–71. http://dx.doi.org/10.1530/acta.0.1200667.
Повний текст джерелаАнотація:
Abstract. The validity of estimation of the production rates of T3 and rT3 in man based on noncompartmental analysis of blood-derived data has been questioned owing to incomplete exchangeability of T3 and rT3 between plasma and extrathyroidal tissues in which a local production of these iodothyronines takes place. The possible existence of a nonexchangeable or hidden pool of T3 and rT3 would result in an underestimation of the daily production. By contrast, the production rate of T4 can be estimated reliably using noncompartmental analysis. We have studied 16 women with pretreatment severe hypothyroidism on constant levothyroxine therapy. Simultaneous measurements of T4, T3 and rT3 production rates were performed using bolus injection of radiolabelled iodothyronines. The tracers were isolated from plasma using gel separation/antibody extraction, and production rates were calculated by noncompartmental analysis. Mean (± sd) production rate of T4, T3 and rT3 were: 119 ± 43, 40.0 ± 22.0 and 54.9 ± 20.0 nmol · day−1 · (70 kg)−1, respectively. Thus 79.5 ± 7.0% of T4 was deiodinated into T3 and rT3. This leaves 20.5% to other metabolic pathways of T4 and to a possible underestimation of T3 and rT3 production rate. Based on conservative estimates from the literature, the other metabolic pathways of T4 amount: oxidative deamination 1.1%; ether link cleavage 0%; urinary excretion 2.5%; and fecal excretion 14%. Thus, the various metabolic pathways seem to explain 97% of daily produced and degradated T4 in man. Therefore the understimation of T3 and rT3 production rates in man using noncompartmental analysis seems of little if any importance, and existence of a hidden pool of these iodothyronines may be questioned.
29
Sym, Sun Jin, Junshik Hong, Hee Kyung Ahn, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Won-Suk Lee, Jeong-Heum Baek, Yeon Ho Park, and Dong Bok Shin. "A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 488. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.488.
Повний текст джерелаАнотація:
488 Background: We conducted a phase II trial of gemcitabine with S-1 to evaluate the activity and toxicity of such a combination in heavily pre-treated patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after treatment with 5-fluorouracil (5-FU), oxaliplatin and irinotecan. Methods: 34 pts were enrolled, with the following characteristics: 17 (50%) females, median age 57 years (28-72), 28 (82%) ECOG PS 0-1. S-1 was given orally (30 mg/m2) b.i.d for 14 consecutive days and gemcitabine (1000 mg/m2) was given on days 1 and 8, every 21 days, until disease progression and for a maximum of 9 cycles. The primary endpoint was objective response rate (ORR). Results: The median number of cycles was four (range 1-9). ORR was 14.7% (95% confidence interval [CI] 2.8-26.6) and disease control rate was 58.8% (95% CI 42.2-75.3) with five partial responses and fifteen stable diseases. Median duration of disease control was 5.1 months (95% CI 3.3-7.0). Median progression-free survival was 3.2 months (95% CI 2.3-4.1) and median overall survival was 11.8 months (95% CI 7.0-16.5). Grade 3-4 toxicities were neutropenia (12%), anemia (12%), thrombocytopenia (3%) and diarrhea (3%). Conclusions: Combination chemotherapy with gemcitabine and S-1 was well tolerated and efficacious for heavily pre-treated mCRC pts, and could be an alternative for pts with good PS but no further treatment options.
30
Hétu, Bernard. "La déglaciation de la région de Rimouski, Bas-Saint-Laurent (Québec) : indices d’une récurrence glaciaire dans la Mer de Goldthwait entre 12 400 et 12 000 BP." Géographie physique et Quaternaire 52, no. 3 (October 2, 2002): 325–47. http://dx.doi.org/10.7202/004832ar.
Повний текст джерелаАнотація:
La distribution des dépôts de marge glaciaire de la région de Rimouski a été analysée en fonction du cadre morphostructural préglaciaire, caractérisé par un relief appalachien typique dont les barres et les sillons, orientés NE-SO, sont subparallèles à la vallée du Saint-Laurent. Cette étude met en lumière l'influence déterminante du contexte morphostructural sur le mode de déglaciation, tant à l'échelle régionale que locale. L'invasion de la Mer de Goldthwait le long du Saint-Laurent, à partir de 14 000 BP, isole progressivement une calotte glaciaire régionale dans les Appalaches. Vers 13 400 BP, la marge septentrionale de la calotte appalachienne suit le tracé de la limite marine, fixée à 140 m d'altitude entre Rimouski et Luceville. Elle s'est stabilisée le long des premières grandes barres appalachiennes qui représentaient la première ligne d'ancrage de la marge glaciaire après l'invasion marine. Durant la phase de retrait qui suit, entre 13 360 et 12 700 ans BP, des masses de glace résiduelles sont abandonnées dans la vallée de ligne de faille de la Neigette et les sillons appalachiens de Saint-Fabien qui s'encombrent de formes de décrépitude (kames et kettles). Entre 12 400 BP et environ 12 000 BP, la marge glaciaire se stabilise sur le rebord du plateau de Sainte-Blandine, à moins de 13 km du littoral actuel. Cette période se signale par une récurrence glaciaire mise en évidence dans trois sites différents. Les modalités et la chronologie de la déglaciation au-delà de la limite marine ne sont pas connues.
31
Sèdégan, Enagnon Bienvenue Florent, Yao Akpo, Kadoéito Cyrille Boko, Maximilien Azalou, Camus Adoligbé, Christophe Iwaka, Eloi Attakpa, and Ibrahim Alkoiret Traoré. "The Effects of Acute Oral Toxicity of Jatropha multifida and Hyptis suaveolens on Zootechnical Parameters in Local Chickens." World's Veterinary Journal 14, no. 3 (September 25, 2024): 328–37. http://dx.doi.org/10.54203/scil.2024.wvj39.
Повний текст джерелаАнотація:
The substantial use of medicinal plants in traditional poultry farming is a well-established practice. The present study aimed to determine the median lethal dose (LD50) of ethanolic extracts of Jatropha multifida and Hyptis suaveolens in local chickens and to assess the effects of these extracts on feed intake, water intake, and average body weight. The methodology followed OECD Directive 223, which involves administering the highest dose of the extract to the chickens and assessing any mortality. Three homogeneous groups of five chickens each were formed for the limit dose test. The control group received distilled water, while batches 1 and 2 received 700 mg of ethanolic extract of J. multifida and H. suaveolens, respectively. The average body weight of the chickens was 350g ± 20, and the extracts were administered via gavage at a suspension of 2000 mg/kg.bwt of the extract dissolved in water. The results of the phytochemical tests indicated the presence of several chemical compounds known for their therapeutic effects. The productivity of the extract was 2.75 ± 0.19 for J. multifida and 3.3 ± 0.27 for H. suaveolens. After administration of the suspensions, observation for 14 days revealed no mortality. This finding indicated that the LD50 of the utilized ethanolic extracts exceeds the limit dose (2000 mg/kg.bwt). However, feed intake (49 ± 3 > 46±4) and average body weight (436 ± 31 > 388 ± 37) in batch 2 were significantly higher than those in batch 1. Future research should explore the subacute toxicity of J. multifida and H. suaveolens across various chicken breeds.
32
Habib, Nazia, Sajid Hussain Awan, Shaheryar Naveed, and Chaudhry Shoaib Akhtar. "Effectiveness of Interpersonal Leadership for Engagement and Task Performance of Nurses." SAGE Open 10, no. 2 (April 2020): 215824402092442. http://dx.doi.org/10.1177/2158244020924429.
Повний текст джерелаАнотація:
Transformational leadership has been studied as an essential trait for nurse leaders in the past; however, there is a dearth of studies on interpersonal leadership which is a combined construct of transformational leadership and interactional justice. The main objective of this article was to examine the relationship between interpersonal leadership and task performance. A cross-sectional research design was adopted for this study. 700 questionnaires were circulated among nurses from 14 major hospitals across the country. Out of these, 336 nurses replied. The final usable sample size was 283 full-time nurses, out of which 91.8% were female. The online and paper-based instruments were floated twice, at different timings with different cover letters to avoid common method bias. Nurses perceive that interpersonal leadership can significantly enhance their task performance. Similarly the study also found significant mediation of work engagement in the positive relationship between interpersonal leadership and task performance. Moreover, there was no significant difference between public and private sector nurses about interpersonal leadership and its relationship with work engagement and task performance. Interpersonal leadership has been found as significantly and positively effective toward work engagement and task performance of nurses working both in public and private sector hospitals. The results establish that by adopting the interpersonal leadership style, a nurse leader can enhance the work engagement of her followers. The study suggests that interpersonal leadership should be adopted as a total concept in nurse management to achieve better results in terms of work engagement and task performance.
33
Guo, Changying, Xiaobing Li, Shengjia Chen, Yongqiang Ye, and Weimin Mao. "Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005)." Journal of Clinical Oncology 43, no. 4_suppl (February 2025): 459. https://doi.org/10.1200/jco.2025.43.4_suppl.459.
Повний текст джерелаАнотація:
459 Background: Surgery represents a primary radical treatment for esophageal cancer, However, the risk of recurrence remains noteworthy after surgical resection, underscoring the need for more effective and tolerable postoperative regimens for esophageal squamous cell carcinoma (ESCC). Benmelstobart, a novel PD-L1 blockade, demonstrated promising antitumor activity when combined with anlotinib, an antiangiogenic agent, in the treatment of various tumors including advanced ESCC (NCT05038813) and biliary tract cancer (NCT03996408). Therefore, ALTER-E005 study aimed to evaluate the efficacy and safety of combining anlotinib with benmelstobart as adjuvant therapy in patients (pts) with ESCC. Methods: This was a single-arm, multi-center phase Ⅱ clinical trial. Thirty pts (≥18 years) with histologically confirmed T1-2N1-3M0 or T3-4NanyM0 ESCC who had undergone radical (R0) resection with no recurrence 6 to 12 weeks after surgery and an ECOG PS ≤ 1 were eligible for enrollment. Enrolled pts received oral anlotinib (12 mg, days 1-14) and intravenous benmelstobart (1200 mg, day 1) every 3 weeks for up to 16 cycles or until disease recurrence. The primary endpoint was disease recurrence free (DFS). while secondary endpoints included safety, 1-year DFS rate, 3-year DFS rate, 1- year overall survival (OS) rate, and 3-year OS rate. Results: As of the data cut-off date (September 20, 2024), a total of 30 patients were enrolled with a median age of 67. Among the 30 surgically resected patients with ESCC, 26 (86.7%) had an ECOG score of 1, and 25 (83.3%) were male. According to the eighth edition of the AJCC Cancer Staging Manual, 9 (30.0%) were classified as stage Ⅱ, and 21 (70.0%) were classified as stage Ⅲ. As of the data cut-off date, the median follow-up time was 8.9 months (95% CI: 7.9-12.3). Four pts experienced disease recurrence, and the median duration of DFS has not yet been reached, with 6-month and 1-year DFS rates of 95.7% (95% CI, 72.9%-99.4%), 84.0% (95% CI, 57.7%-94.6%) respectively. Currently, 13 pts are still undergoing therapy. Out of the total 30 patients, 9 (30%) experienced grade 3 treatment-emergent adverse events (TEAEs). No grade 4 or higher TEAEs were observed. The grade 3 TEAEs included hand-foot syndrome (10.0%), hypertension (3.3%), abnormal liver function (3.3%), immune-related hepatitis (3.3%), pneumonia (3.3%), hyperglycemia (3.3%) Lymphocyte count decreased (3.3%), acute cholecystitis (3.3%) and syncope (3.3%). Conclusions: This study highlighted the promising efficacy and safety preliminarily of combining anlotinib with benmelstobart as adjuvant therapy in patients with ESCC who underwent radical (R0) resection and showed no recurrence 6 to 12 weeks after surgery. Clinical trial information: NCT05252078 .
34
Deriglazova, Galina M., and Ekaterina А. Semenenko. "THE INFLUENCE OF BIOPREPARATIONS ON THE GROWTH AND DEVELOPMENT OF PEAS IN DIFFERENT TYPES OF SOILS." Land Reclamation and Hydraulic Engineering 14, no. 4 (2024): 322–36. http://dx.doi.org/10.31774/2712-9357-2024-14-4-322-336.
Повний текст джерелаАнотація:
Purpose: to determine the effect of soaking Jaguar pea seeds in a solution with biopreparations, such as “Biohumus Concentrate” and “Biohumate + 9 Microelements”, on the crop growth and development in various soils. Materials and methods. Laboratory studies were conducted in 2024 at Federal Agricultural Kursk Research Center. Pea seeds were germinated in germination chambers of 100 pcs. for 4 and 8 days on various soils. Before germination, the seeds were pre-soaked for 24 h in tap water, in “Biohumus Concentrate” diluted with water at a dose of 10 ml of the preparation per 1 l of water, in “Biohumate + 9 Microelements” at a dose of 10 ml of the preparation per 1 l of water, then the results were compared with the control option without additional soaking. Results. It was found that the maximum effect on plant height (5.8 cm) and root length (15.9 cm), wet (17.0 g) and dry (1.68 g) plant weight was observed when using the preparation “Biohumate + 9 Microelements” and the soil Terra Vita. Wet and dry weight of the roots of 100 plants was the highest when using the preparation “Biohumate + 9 Microelements” on all the studied soils (the increase relative to the control was 18.7–61.7 and 17.9–70.0 %, respectively). In all other experimental variants, no difference in the effectiveness of the biopreparations was found. With a decrease in soil fertility, seed germination and dry weight of roots decreased, but the amount of dry matter in pea roots increased. The wet weight of 100 roots of pea plants increased under the influence of biopreparations (r = 0.55, α = 0.05) and decreased with a decrease in soil fertility (r = –0.69, α = 0.05). Conclusion. It was found that preliminary soaking of pea seeds of the Jaguar variety in a solution with biopreparations “Universal Biohumus Concentrate” and “Biohumate + 9 Microelements” for 1 day causes an increase in the germination energy of seeds, plant height, root length, wet and dry weight of plants and roots on all studied soils.
35
Zhang, Jia-Yue, Xing-Yu Liu, and Shuang-Jiang Liu. "Phycicoccus cremeus sp. nov., isolated from forest soil, and emended description of the genus Phycicoccus." International Journal of Systematic and Evolutionary Microbiology 61, no. 1 (January 1, 2011): 71–75. http://dx.doi.org/10.1099/ijs.0.020842-0.
Повний текст джерелаАнотація:
A bacterial strain, designated V2M29T, was isolated from forest soil collected in the Changbai Mountains, Heilongjiang Province, China. Cells of strain V2M29T were Gram-positive, rod-shaped (0.5–0.8 μm in diameter and 1.5–2.0 μm in length), strictly aerobic and non-motile. Colonies produced on R2A agar plates were creamy, smooth, circular and 0.3–0.8 mm in diameter. Strain V2M29T grew at 14–35 °C (optimum, 29 °C), at pH 4.1–10.0 (optimum, pH 7.0–8.0) and in the presence of 0–7.0 % (w/v) NaCl (optimum, 0–2.0 %). Strain V2M29T contained MK-8(H4) as the major respiratory quinone and iso-C15 : 0 (20.9 %), iso-C16 : 0 (18.5 %), C17 : 1 ω8c (16.7 %) and 10-methyl-C17 : 0 (9.2 %) as the major cellular fatty acids. The cell-wall peptidoglycan type was based on meso-2,6-diaminopimelic acid and the acyl type of the muramic acid was acetyl. Diphosphatidylglycerol, phosphatidylinositol and six unknown glycolipids were the major polar lipids. The G+C content of the DNA was 72.0 mol% (T m). 16S rRNA gene sequence analysis indicated that strain V2M29T was phylogenetically related to members of the genus Phycicoccus, with sequence similarities ranging from 96.6–97.8 %. The DNA–DNA relatedness values of strain V2M29T to Phycicoccus dokdonensis DS-8T and Phycicoccus bigeumensis DSM 19264T were 32.5±3.3 % and 29.2±2.3 %, respectively. Based on these results, it is concluded that strain V2M29T represents a novel species of the genus Phycicoccus, for which the name Phycicoccus cremeus sp. nov. is proposed, with V2M29T (=CGMCC 1.6963T =NBRC 104261T) as the type strain.
36
Hatahet, Wael, Abdul Soofi, Oyonumo Ntekim, and Thomas Fungwe. "Plasma Lipid Profiles of Transgenic mice expressing the Human ApoB100XCETP are altered differentially by Diets enriched with defined Fatty Acids." Current Research in Nutrition and Food Science Journal 3, no. 3 (December 16, 2015): 207–18. http://dx.doi.org/10.12944/crnfsj.3.3.04.
Повний текст джерелаАнотація:
Dietary fat is known to modulate plasma lipid profiles. Synthesis of high density lipoproteins (HDL), which has protective effects on vascular disease is also influenced by dietary fats, but the mechanisms are unclear. The hapoB100XCETP transgenic mouse was used to investigate the effects of fatty acids on the metabolism of plasma lipoproteins, including the pathway leading to synthesis HDL. Male transgenic mice were fed with diets formulated to provide TG (33% energy) as tripalmitin (TP), triolein (TO), tristearin (TS) or equicaloric substitution of fat with carbohydrate (sucrose) for 4 weeks. Analysis of plasma profile showed that HDL-cholesterol were 53.7+14; 64.6+8.6; 50.2+3.3; 47.0+9.2 and 45.2+4.9 mg/dL for control, oleate, palmitate, stearate and sucrose based diets, respectively. LDL-cholesterol levels were 51.7+7.0; 23.1+7.0; 38.9+2.2; 75.1+1.8 and 46.8.1.0 mg/dl, for control, TO, TP, TS and sucrose, respectively. Hepatic Lecithin-cholesterol acyltransferase (LCAT) protein levels increased by 2-fold in mice fed TS or TO diets, compared to TP, while sucrose had no effect. The scavenger receptor class B type I (SR-B1) which plays an important role in meditating the uptake of HDL-derived cholesterol and cholesteryl ester in the liver and steroidogenic tissues increased in livers of animals fed TP and TO, while TS and sucrose did not have a similar effects. These results suggests that fatty acids can uniquely impact HDL, in addition, the ApoB100XCETP mouse is a useful model for the evaluation of how dietary components affect the risk of developing atherosclerosis and heart disease.
37
Voskanyan, S. E., A. I. Artemyev, A. I. Sushkov, K. K. Gubarev, D. S. Svetlakova, M. V. Popov, V. S. Rudakov, A. N. Bashkov, E. V. Naydenov, and M. Muktarzhan. "Modified cavocavostomy technique for deceased donor liver transplantation." Transplantologiya. The Russian Journal of Transplantation 14, no. 2 (June 14, 2022): 142–58. http://dx.doi.org/10.23873/2074-0506-2022-14-2-142-158.
Повний текст джерелаАнотація:
Rationale. The refinement of liver transplantation technique, the development and implementation of new surgical technologies into clinical practice, including those for inferior vena cava reconstruction, are important for the improvement of surgery outcomes.The study purposes were to present our own modification of cavocavostomy and options for its technical implementation in deceased donor liver transplantation, as well as to study the clinical effects and the impact of new surgical technique on the outcomes.Material and methods. A retrospective, single-centre study included the data from 109 consecutive deceased donor liver transplantations performed between 2012 and 2021. In 106 procedures, inferior vena cava reconstruction was performed either according to the classic technique (group 1, n=23, 22%), or using our own modification of cavocavostomy (group 2, n=83, 78%). To assess the clinical efficacy and safety of the new surgical technique, we compared the characteristics of donors and recipients, intraoperative parameters, features of early postoperative course, incidence of surgical complications, initial function, immediate and long-term graft survival. Three piggyback procedures were not included in the comparative analysis.Results. Two groups were generally comparable in terms of the characteristics of donors and recipients, however, the classic inferior vena cava was significantly more often used during transplants for unresectable parasitic liver lesions (17% vs. 1%, p=0.008) and retransplantations (30% vs. 5%, p=0.002). There were no statistically significant differences in the main intraoperative parameters between groups 1 and 2. The duration of transplantations was 8.0 h (interquartile range: 6.5–8.5 h) and 7.0 h (interquartile range: 6.0–8.0 h), p=0.112; anhepatic phase lasted 70 min (interquartile range: 60–75 min) and 70 min (interquartile range: 59–90 min), p=0.386; warm ischemia time was 45 min (interquartile range: 38–52 min) and 45 min (interquartile range: 38–50 min), p=0.690; inferior vena cava was clamped for 47 min (interquartile range: 40–55 min) and 50 min (interquartile range: 40–55 min), p=0.532. The volumes of intraoperatively transfused blood components were, respectively: packed red cells 630 ml (interquartile range: 0–1280 ml) and 600 ml (interquartile range: 0–910 ml), p=0.262; blood reinfusion 770 ml (interquartile range: 360–1200 ml) and 700 ml (interquartile range: 0–1200 ml), p=0.370; fresh frozen plasma 2670 ml (interquartile range: 2200 and 3200 ml) and 2240 ml (interquartile range: 1880–2900 ml), p=0.087.When using classic caval reconstruction technique, the proportion of grafts with early dysfunction was higher: 44% vs. 17% (p=0.011), due to the higher rate of retransplantations in this group. The incidence of acute kidney injury (by RIFLE > I) was 35% and 19% (p=0.158), the need for renal replacement therapy was 22% and 15% (p=0.520) in group 1 and group 2, respectively. The total incidence of surgical complications in the early postoperative period was 30% and 16%, p=0.110.Conclusions. The proposed technique of cavocavostomy can be considered as a priority method for caval reconstruction during deceased donor liver transplantation, with the exception of specific indications for the use of the classic technique (retransplantation, involvement of the inferior vena cava wall in a parasitic process or presentation of a tumor node to it, as well as in cases of widespread adhesive process in the abdominal cavity, hypertrophy of the 1 segment of the native liver, the presence and location of TIPS, thinning of the wall of the retrohepatic inferior vena cava, the risk of graft compression with its large size).The choice of the cavocavostomy variant should be carried out taking into account the size ratio of the graft to the recipient's right subdiaphragmatic space, and the topography features of the recipient's hepatic veins.
38
Lindgren, Antti, Sarah Burt, Ellie Bragan Turner, Atte Meretoja, Jin-Moo Lee, Thomas M. Hemmen, Mark Alberts, Robin Lemmens, Mervyn DI Vergouwen, and Gabriel JE Rinkel. "Hospital case-volume is associated with case-fatality after aneurysmal subarachnoid hemorrhage." International Journal of Stroke 14, no. 3 (July 18, 2018): 282–89. http://dx.doi.org/10.1177/1747493018790073.
Повний текст джерелаАнотація:
Background Inverse association between hospital case-volume and case-fatality has been observed for various nonsurgical interventions and surgical procedures. Aims To study the impact of hospital case-volume on outcome after aneurysmal subarachnoid hemorrhage (aSAH). Methods We included aSAH patients who underwent aneurysm coiling or clipping from tertiary care medical centers across three continents using the Dr Foster Stroke GOAL database 2007–2014. Hospitals were categorized by annual case-volume (low volume: <41/year; intermediate: 41–70/year; high: >70/year). Primary outcome was 14-day in-hospital case-fatality. We calculated proportions, and used multiple logistic regression to adjust for age, sex, differences in comorbidity or disease severity, aneurysm treatment modality, and hospital. Results We included 8525 patients (2363 treated in low volume hospitals, 3563 treated in intermediate volume hospitals, and 2599 in high-volume hospitals). Crude 14-day case-fatality for hospitals with low case-volume was 10.4% (95% confidence interval (CI) 9.2–11.7%), for intermediate volume 7.0% (95% CI 6.2–7.9%; adjusted odds ratio (OR) 0.63 (95%CI 0.47–0.85)) and for high volume 5.4% (95% CI 4.6–6.3%; adjusted OR 0.50 (95% CI 0.33–0.74)). In patients with clipped aneurysms, adjusted OR for 14-day case-fatality was 0.46 (95% CI 0.30–0.71) for hospitals with intermediate case-volume and 0.42 (95% CI 0.25–0.72) with high case-volume. In patients with coiled aneurysms, adjusted OR was 0.77 (95% CI 0.55–1.07) for hospitals with intermediate case-volume and 0.56 (95% CI 0.36–0.87) with high case-volume. Conclusions Even within a subset of large, tertiary care centers, intermediate and high hospital case-volume is associated with lower case-fatality after aSAH regardless of treatment modality, supporting centralization to higher volume centers.
39
Tomelleri, A., C. Campochiaro, S. Sartorelli, N. Farina, E. Baldissera, and L. Dagna. "FRI0191 CRANIAL-LIMITED AND LARGE-VESSEL GIANT CELL ARTERITIS: PRESENTING FEATURES AND OUTCOME." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 678.3–679. http://dx.doi.org/10.1136/annrheumdis-2020-eular.705.
Повний текст джерелаАнотація:
Background:Giant cell arteritis (GCA) comprises two main phenotypes: cranial (C) and large-vessel (LV) disease1. A full baseline steroid-free vascular imaging evaluation is required to properly diagnose LV involvement2Objectives:To compare presenting and prognostic features of LV-GCA and C-GCA patients after an adequate vascular imaging evaluation at baselineMethods:Data from GCA patients followed-up at our Institution were retrospectively collected. Only patients who underwent large-vessel imaging (PET, CTA, MRA) at disease onset or within 1 week after steroid introduction were included. Patients with evidence of LV involvement were classified as LV-GCA. Differences between LV-GCA and C-GCA patients regarding presenting features, treatment, prognosis were evaluated. Non-parametric tests were usedResults:In our cohort, we identified 161/280 patients who underwent LV-imaging study at baseline. Of these, 100 (62.1%) had signs of LV inflammation. Table 1 compares demographic features, diagnostic delay, pre-existing comorbidities and complementary treatment between the 2 groups. Table 2 compares disease features at diagnosis. Mean follow-up was similar between LV- and C-GCA patients (31.8±31.8 vs 27.8±29.1 months; 70% vs 73.8% followed-up ≥12 months). Corrected cumulative prednisone dose (CCPD, grams/months) was equivalent (LV, 0.67±0.57; C, 0.87±1.37; p=0.871). A DMARD was added in 73% of LV- and in 55.7% of C-GCA patients (p=0.027), but, notably, it was introduced at baseline in 52% of LV- vs 23.5% of C-GCA patients (p=0.006). CCPD was equivalent even considering only patients who did not receive DMARDs (LV, 0.92±0.81; C, 0.94±1.18; p=0.522). Frequency of relapses was not significantly different (LV, 51%; C, 57.3%, p=0.515), even when considering only DMARD-receiving patients (LV, 36.1%; C, 38.2%, p=0.833). Aortic aneurysms incidence at 5 years was similar (LV, 17.3%; C, 15.7%; p=0.826). Rate of metabolic and infective complications was similar, in terms of arterial hypertension (LV, 3%; C, 0%, p=0.286), diabetes (2% vs 0%, p=0.524), osteoporotic fractures (7% vs 5%, p=0.742), severe infections (3% vs 3.3%, p=1)Table 1.Demographic features, diagnostic delay, pre-existing comorbidities, and complementary treatment at baseline in LV and C-GCA patientsLV imaging +n=100 (%)LV imaging-n=61 (%)p-valueAge (years)73.2 ± 8.976 ± 8.80.018Sex (female)65 (65)40 (65)1Diagnostic delay (months)3.5 ± 4.62.3 ± 4.90.001Pre-existing comorbidities- CAD3 (3)7 (11.5)0.043- Diabetes4 (4)6 (9.8)0.181- Dyslipidemia17 (17)17 (27.9)0.114- Hypertension42 (42)34 (55.7)0.105- Stroke3 (3)3 (5)0.674- Cancer20 (20)6 (9.8)0.122Ongoing complementary treatment- Antiplatelet18 (18)15 (25)0.322- Anticoagulant1 (1)6 (9.8)0.012- Statin14 (14)14 (23)0.198Table 2.Diseases features at onset in LV and C-GCA patientsLV imaging +n=100 (%)LV imaging-n=61 (%)p-valueTemporal biopsy positive17/31 (55)9(43)0.573Symptoms- Headache65 (65)52 (85)0.006- Jaw claudication22 (22)20 (32.8)0.142- Scalp tenderness31 (31)26 (42.6)0.174- Ocular symptoms14 (14)20 (32.8)0.006- Ischemic optic neuropathy7 (7)17 (27.9)<0.001- Stroke3 (3)0 (0)0.290- Polymyalgia rheumatica42 (42)31 (50.8)0.328- Fever44 (44)12 (19.7)0.002- Fatigue72 (72)21 (34.4)<0.001- Weight loss37 (37)7 (11.5)<0.001- Cough10 (10)1 (1.6)0.053Laboratory findings, mean- C-reactive protein, mg/L80.8 ± 60.865.7 ± 58.20.057- Erythrocyte sedimentation rate76.8 ± 3071.5 ± 270.360- Hemoglobin, g/dL11.4 ± 1.512 ± 1.60.007- Platelet count389.4 ± 116.6366.8 ± 125.20.758Conclusion:LV-GCA patients are younger and suffer of a greater diagnostic delay. Although a greater systemic inflammation seems to be a feature of LV-GCA patients, the vascular prognosis is similar to C-GCA patients, who, conversely, have a greater incidence of ocular complicationsReferences:[1]Dejaco C, et al. Nat Rev Rheumatol (2017)[2]Kermani T, et al. Rheumatology (2019)Disclosure of Interests:Alessandro Tomelleri: None declared, Corrado Campochiaro Speakers bureau: Novartis, Pfizer, Roche, GSK, SOBI, Silvia Sartorelli: None declared, Nicola Farina: None declared, Elena Baldissera Speakers bureau: Novartis, Pfizer, Roche, Alpha Sigma, Sanofi, Lorenzo Dagna Grant/research support from: Abbvie, BMS, Celgene, Janssen, MSD, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, SG, SOBI, Consultant of: Abbvie, Amgen, Biogen, BMS, Celltrion, Novartis, Pfizer, Roche, SG, and SOBI
40
Haddad, Nicholas, Patrick Scheffler, Mohamed Aly Elkoushy, Olivier Court, Nicolas V. Christou, Ross E. Andersen, and Sero Andonian. "Long-term incidence of urolithiasis post-bariatric surgery." Canadian Urological Association Journal 8, no. 9-10 (October 22, 2014): 688. http://dx.doi.org/10.5489/cuaj.1942.
Повний текст джерелаАнотація:
Introduction: The risk of urolithiasis post-Roux-en-Y gastric bypass (RYGB) surgery is higher when compared to the general population. Calcium and vitamin D supplementation is routinely prescribed to these patients, yet compliance with these supplements is unknown. The aim of this study was to assess the incidence of symptomatic de novo urolithiasis post-RYGB and compliance with calcium and vitamin D supplementation.Methods: A standardized telephone questionnaire was administered to patients who underwent RYGB between 1996 and 2011. Personal and medical histories were obtained with emphasis on episodes of symptomatic urolithiasis and calcium and vitamin D supplementation.Results: The response rate was 48% with 478 patients completing the telephone questionnaire. After a mean follow-up of 7.0 years (range: 1-15), the incidence of post-RYGB symptomatic urolithiasis was 7.3%, while the rate of de novo symptomatic urolithiasis was 5%. The overall median time to present with symptomatic urolithiasis was 3.1 years, with 3.3 years for de novo stone-formers, and 2.0 years for recurrent stone-formers (p = 0.38). In de novo stone-formers, 33% presented with symptomatic urolithiasis 4 to 14 years postoperatively. Compliance with calcium and vitamin D supplementation was 56% and 51%, respectively.Conclusions: Despite recall bias and lack of confirmatory imaging studies, a high postoperative incidence of symptomatic urolithiasis was found in a large sample of post-RYGB patients. A third of patients with de novo stones, presented with symptomatic urolithiasis 4 to 14 years postoperatively. Compliance with postoperative calcium and vitamin D supplementation was poor and needs improvement.
41
Tubiello, Francesco N., Kevin Karl, Alessandro Flammini, Johannes Gütschow, Griffiths Obli-Laryea, Giulia Conchedda, Xueyao Pan, et al. "Pre- and post-production processes increasingly dominate greenhouse gas emissions from agri-food systems." Earth System Science Data 14, no. 4 (April 14, 2022): 1795–809. http://dx.doi.org/10.5194/essd-14-1795-2022.
Повний текст джерелаАнотація:
Abstract. We present results from the FAOSTAT emissions shares database, covering emissions from agri-food systems and their shares to total anthropogenic emissions for 196 countries and 40 territories for the period 1990–2019. We find that in 2019, global agri-food system emissions were 16.5 (95 %; CI range: 11–22) billion metric tonnes (Gt CO2 eq. yr−1), corresponding to 31 % (range: 19 %–43 %) of total anthropogenic emissions. Of the agri-food system total, global emissions within the farm gate – from crop and livestock production processes including on-farm energy use – were 7.2 Gt CO2 eq. yr−1; emissions from land use change, due to deforestation and peatland degradation, were 3.5 Gt CO2 eq. yr−1; and emissions from pre- and post-production processes – manufacturing of fertilizers, food processing, packaging, transport, retail, household consumption and food waste disposal – were 5.8 Gt CO2 eq. yr−1. Over the study period 1990–2019, agri-food system emissions increased in total by 17 %, largely driven by a doubling of emissions from pre- and post-production processes. Conversely, the FAOSTAT data show that since 1990 land use emissions decreased by 25 %, while emissions within the farm gate increased 9 %. In 2019, in terms of individual greenhouse gases (GHGs), pre- and post-production processes emitted the most CO2 (3.9 Gt CO2 yr−1), preceding land use change (3.3 Gt CO2 yr−1) and farm gate (1.2 Gt CO2 yr−1) emissions. Conversely, farm gate activities were by far the major emitter of methane (140 Mt CH4 yr−1) and of nitrous oxide (7.8 Mt N2O yr−1). Pre- and post-production processes were also significant emitters of methane (49 Mt CH4 yr−1), mostly generated from the decay of solid food waste in landfills and open dumps. One key trend over the 30-year period since 1990 highlighted by our analysis is the increasingly important role of food-related emissions generated outside of agricultural land, in pre- and post-production processes along the agri-food system, at global, regional and national scales. In fact, our data show that by 2019, pre- and post-production processes had overtaken farm gate processes to become the largest GHG component of agri-food system emissions in Annex I parties (2.2 Gt CO2 eq. yr−1). They also more than doubled in non-Annex I parties (to 3.5 Gt CO2 eq. yr−1), becoming larger than emissions from land use change. By 2019 food supply chains had become the largest agri-food system component in China (1100 Mt CO2 eq. yr−1), the USA (700 Mt CO2 eq. yr−1) and the EU-27 (600 Mt CO2 eq. yr−1). This has important repercussions for food-relevant national mitigation strategies, considering that until recently these have focused mainly on reductions of non-CO2 gases within the farm gate and on CO2 mitigation from land use change. The information used in this work is available as open data with DOI https://doi.org/10.5281/zenodo.5615082 (Tubiello et al., 2021d). It is also available to users via the FAOSTAT database (https://www.fao.org/faostat/en/#data/EM; FAO, 2021a), with annual updates.
42
Ansa, Benjamin, Tom Adamkiewicz, Yvonne Fry-Johnson, Gregory Strayhorn, Barbara Moore, and George S. Rust. "Outpatient Visits, Hospitalizations and Emergency Department Visits Among Patients with Sickle Cell Disease On Medicaid: Trends in 14 USA States, 2006–2007." Blood 120, no. 21 (November 16, 2012): 3181. http://dx.doi.org/10.1182/blood.v120.21.3181.3181.
Повний текст джерелаАнотація:
Abstract Abstract 3181 Sickle cell disease (SCD) is an inherited hematological disorder affecting 90,000–100,000 Americans. Public insurance accounts for the major method of reimbursement for medical care utilization in this population. Few published population-based studies describe outpatient visits, hospitalizations and emergency department visits together. This study examined rates of hospitalizations, outpatient visits (OPV) and emergency department visits (EDV) among children and adults with SCD across fourteen states of the United States, using a relational claims database, to determine any differences across age groups, genders and states (Medicaid Analytic eXtract [MAX] files, of the Center for Medicare and Medicaid Services). Visits information was extracted using ICD-9-CM codes for SCD, as well as procedure codes (cpt) to determine OPV and EDV. All SCD cases with 24 months continuous Medicaid eligibility for the period under study (2006 to 2007) were identified, and the pattern of medical care utilization was examined. A total of 19,168 pediatric and adult SCD patients were identified to have enrolled in Medicaid with eligibility for the years 2006 and 2007. The mean age was 22.06 years; range: <1year-93years; males and females accounted for 7,402(38.6%) and 11,763(61.4%) respectively with 3 cases of unknown gender. The highest number of cases (2,353[12.3%]) presented in Florida, while Georgia and Louisiana followed with 2,130(11.1%) and 1,883(9.8%) patients respectively (other states included Alabama, Arkansas, Kentucky, Maryland, Missouri, Mississippi, North & South Carolina, Tennessee, Texas and Virginia). The <1–10 years age group represented 25.2% of cases, and majority of the cases were 11–20 years old (27.4%), with a decline in the number of cases as the age increased. Patients identified as Blacks/African Americans made up 80.5% of the SCD population. After the age of 21 years, there were considerably more female SCD patients enrolled in Medicaid, compared to males. There were 94,891 OPV recorded within the two year period, 61,762 hospitalizations and 146,163 EDV. The yearly rate for OPV ranged from 0.5–15.1 per 1000 visits, for hospitalization, 0.4–8.9 per 1000 visits, and for EDV, 2–22.9 per 1000 visits. Patients that were in the <1–10 years age group had the most OPV (15.1 per 1,000 visits yearly rate), and those over 50 years had the least OPV (2.1 per 1000 visits yearly). Hospitalization and EDV rates were highest among patients that were between 21 and 30 years old (8.9 and 22.9 per 1,000 visits yearly, respectively), and lowest for the over 50 years group (1.5 and 2.0 per 1000 visits yearly). In summary, patterns medical service utilization in patients with SCD on Medicaid, representing approximately 1/5 to 1/4 of the estimated USA patient population. Utilization of care changed significantly as children transitioned into adulthood: OPV decreased, while hospitalization and, in particular, EDV increased and peaked in young adults. The emergency department, as the commonest place for service among young adults with SCD, may be a strategic focal point for promoting disease prevention programs. Medical Care Utilization by SCD Patients by Age (years) and Gender, 2006–2007 (MAX)* Age (years) Total # of SCD Patients N=19168 (100%) Total OPV N=94891 (100%) Yearly rate of OPV/1000 Total EDV N=146163 (100%) Yearly rate of EDV/1000 Total Hosp. N=61762 (100%) Yearly rate of Hosp./1000 <1–10 4825 (25.2%) 30193 (31.8%) 15.1 6043 (4.1%) 3.0 10564 (17.1%) 5.3 11–20 5247 (27.4%) 27990 (29.5%) 14 35599 (24.4%) 17.8 15942 (25.8%) 8.0 21–30 4480 (23.4%) 16552 (17.4%) 8.3 45820 (31.3%) 22.9 17735 (28.7%) 8.9 31–40 2166 (11.3%) 9315 (9.8%) 4.7 23418 (16.0%) 11.7 9101 (14.7%) 4.6 41–50 1444 (7.5%) 6657 (7.0%) 3.3 11780 (8.1%) 5.9 5428 (8.8%) 2.7 51–60 683 (3.6%) 3255 (3.4%) 1.6 4097 (2.8%) 2.0 2182 (3.5%) 1.1 >60 323 (1.7%) 929 (1.0%) 0.5 19406 (13.3%) 9.7 810 (1.3%) 0.4 p value (Age) 0.0001 0.0001 0.0001 Gender Female 11763 (61.4%) 57297 (60.4%) 28.6 88811 (60.8%) 44.4 37633 (60.9%) 18.8 Male 7402 (38.6%) 37582 (39.6%) 18.8 57346 (39.2%) 28.7 24125 (39.1%) 12.1 Unknown 3 (0%) 12 (0%) 6 (0%) 4 (0%) p value (Gender) 0.0001 0.0001 0.0001 Yearly Rate of Medical Care Utilization by SCD Patients by Age (years)/1000 visits (MAX)* *MAX: Medicaid Analytic eXtract files 2006–2007 Disclosures: No relevant conflicts of interest to declare.
43
Leite, Jessica Cristina, Jéssica Caroliny de Jesus Neves, Leonardo George Victorio Vitor, and Dirce Shizuko Fujisawa. "Evaluation of postural control in children and adolescents with down syndrome aged eight to twelve years old." Journal of Human Growth and Development 28, no. 1 (March 12, 2018): 50. http://dx.doi.org/10.7322/jhgd.127335.
Повний текст джерелаАнотація:
Introduction: Down Syndrome is a genetic disorder caused by the presence of the third copy of chromosome 21 (total or partial). The syndrome occurs in approximately one out of every 700 – 1000 newborns per year. Objective:To analyze postural control (PC) of children and adolescents with Down Syndrome (DS) and to compare differences regarding age, sex, nutritional status, and physical activity (PA) levels. Methods: In this cross-sectional study, a convenience sample composed of 21 children and adolescents (9 girls) was categorized according to age: G1 (8 to 9 years old; n = 8), G2 (10 years old; n = 7), and G3 (11 to 12 years old; n = 6), Score-Z: eutrophic (n = 9) and overweight (n = 12), and PA level: practitioners (n = 7) and non-practitioners (n = 14). PC was assessed in the force platform (FP), in the standing position, with feet together during 30 seconds. The variables analyzed were the center of pressure area (COP) and the mean velocities of anteroposterior and mediolateral oscillation (VEL-AP and VEL-ML). Shapiro-Wilk test was used to test the normality of data. Kruskal-Wallis, Dunn’s, and Mann Whitney tests were performed to analyze associations with PC. Statistical significance was set at p<0.05. Results: The median COP, VEL-AP and VEL-ML were 3.55 [2.13 – 6.82] , 2.81 [2.32 – 3.16], and 2.98 [2.42 – 3.43], respectively. There were no differences in PC regarding sex, body mass index and PA level. The adolescents in G3 presented lower values of VEL-AP (G1=2,88 [2,82 – 3,21]; G2= 2,94 [2,35 – 3,39]; G3= 2,27 [2 – 2,3]) and VEL-ML (G1= 3,22 [3,14 – 3,68]; G2= 2,91 [2,52 – 3,63]; G3= 2,34 [2,1 – 2,39]). Conclusion: Sex, nutritional status, and PA level did not affect COP area and AP-VEL and ML-VEL. However, strategies were affected by age, as observed by differences in velocity, but did not affect the COP area.
44
Jlali, Maamer, Marta Isabel Gracia, Héctor Perez, Óscar Casabuena, Pierre Cozannet, and Aurélie Preynat. "250 Key drivers of a new multi-carbohydrase and phytase complex value for growing-finishing pigs: energy or amino acids?" Journal of Animal Science 98, Supplement_4 (November 3, 2020): 179. http://dx.doi.org/10.1093/jas/skaa278.329.
Повний текст джерелаАнотація:
Abstract This study aimed to investigate the effects of reductions in energy and amino acids on the efficacy of supplementing corn-wheat-soybean meal diets with a multi-carbohydrase and phytase complex (MCPC) on growth performance and ATTD of energy and nutrients. A total of 700 pigs (BW = 29.5; SD = 4.2 kg) were housed in 70 pens and fed 5 diets (14 pens/diet). Diets were positive control (PC); and negative control 1 (NC1) or negative control 2 (NC2) without or with MCPC. The PC diet was adequate in nutrients according to NRC (2012). Relative to this PC diet, both NC diets were similarly reduced in digestible P (-0.134% unit) and calcium (-0.12% unit) and were differently reduced in NE and dig. AA (NC1 = -173 kcal/kg and -5% dig. AA and NC2 = -124 kcal/kg and -7% dig. AA). Fecal samples were collected from each pen at around 50 kg of BW. Final BW, ADG and feed conversion ratio were impaired (P < 0.05) with the lower nutrient specifications (NC1 and NC2) in comparison with the PC diet. ADFI did not differ among treatments. MCPC supplementation improved the final BW (+2.2%, P = 0.05), ADG (+2.8%, P = 0.05) and feed conversion ratio (-3.3%, P = 0.001). Compared with PC diet, ATTD of DM, OM, CP, EE, energy, Ca and P were reduced in pigs fed NC diets (P < 0.05). The addition of MCPC improved the ATTD of DM (P = 0.001), OM (P = 0.02), CP (P < 0.0001), energy (P = 0.01), Ca (P < 0.0001), and P (P < 0.0001). The present study indicates that the MCPC supplementation was efficient to compensate the dietary protein and amino acid reductions (up to 7%). However, the reduction in dietary energy should be limited below 5% to guarantee feed efficiency and optimal performance.
45
Choi, Young J., Carlos B. Miguez, and Byong H. Lee. "Characterization and Heterologous Gene Expression of a Novel Esterase from Lactobacillus casei CL96." Applied and Environmental Microbiology 70, no. 6 (June 2004): 3213–21. http://dx.doi.org/10.1128/aem.70.6.3213-3221.2004.
Повний текст джерелаАнотація:
ABSTRACT A novel esterase gene (estI) of Lactobacillus casei CL96 was localized on a 3.3-kb BamHI DNA fragment containing an open reading frame (ORF) of 1,800 bp. The ORF of estI was isolated by PCR and expressed in Escherichia coli, the methylotrophic bacterium Methylobacterium extorquens, and the methylotrophic yeast Pichia pastoris under the control of T7, methanol dehydrogenase (PmxaF ), and alcohol oxidase (AOX1) promoters, respectively. The amino acid sequence of EstI indicated that the esterase is a novel member of the GHSMG family of lipolytic enzymes and that the enzyme contains a lipase-like catalytic triad, consisting of Ser325, Asp516, and His558. E. coli BL21(DE3)/pLysS containing estI expressed a novel 67.5-kDa protein corresponding to EstI in an N-terminal fusion with the S � tag peptide. The recombinant L. casei CL96 EstI protein was purified to electrophoretic homogeneity in a one-step affinity chromatography procedure on S-protein agarose. The optimum pH and temperature of the purified enzyme were 7.0 and 37�C, respectively. Among the pNP (p-nitrophenyl) esters tested, the most selective substrate was pNP-caprylate (C8), with Km and k cat values of 14 � 1.08 μM and 1,245 � 42.3 S−1, respectively.
46
Schnell, David, Benjamin Planquette, Asaël Berger, Sybille Merceron, Julien Mayaux, Lucas Strasbach, Stéphane Legriel, Sandrine Valade, Michael Darmon, and Ferhat Meziani. "Cuff Leak Test for the Diagnosis of Post-Extubation Stridor: A Multicenter Evaluation Study." Journal of Intensive Care Medicine 34, no. 5 (March 27, 2017): 391–96. http://dx.doi.org/10.1177/0885066617700095.
Повний текст джерелаАнотація:
Background: Cuff leak test was developed to predict the occurrence of post-extubation stridor (PES). This study evaluated the diagnostic performance of this test in unselected critically ill patients. Methods: Multicenter prospective study including unselected ventilated patients at the time of their first planned extubation. The diagnostic performance of 4 different cuff leak tests was assessed. Results: Post-extubation stridor occurred in 34 (9.4%) of 362 included patients. Compared to patients without PES, patients with PES required more frequently reintubation (6 [17.6%] vs 26 [7.9%], P = .041), prolonged duration of ventilation (6 [3-13] vs 5 [2-9] days, P = .029), and longer intensive care unit (ICU) stay (12 [6-17.5] vs 7.5 [4-13] days, P = .018). However, ICU mortality was similar in both groups (1 [2.9%] vs 23 [7.0%], P = .61). The 4 cuff leak tests display poor diagnostic accuracy: sensitivities ranging from 27% to 46%, specificities from 70% to 88%, positive predictive values from 14% to 19%, and negative predictive values from 92% to 93%. Conclusion: Post-extubation stridor occurs in less than 10% of unselected critically ill patients. The several cuff leak tests display limited diagnostic performance for the detection of PES. Given the high rate of false positives, routine cuff leak test may expose to undue prolonged mechanical ventilation.
47
Christensen, Rachael G., and John R. Hendrickson. "PSXII-11 Evaluation of Yellow-Flowered Subspecies Falcata Alfalfa to Purple Flowered Medicago Sativa for Northern Plains: Productivity, Nutrient Profile, and in Vitro True dry Matter Digestibility." Journal of Animal Science 100, Supplement_3 (September 21, 2022): 285–86. http://dx.doi.org/10.1093/jas/skac247.519.
Повний текст джерелаАнотація:
Abstract The protein content and nitrogen fixation capabilities of alfalfa (Medicago sativa L.) make it valuable in cropland and rangelands. However, the semi-arid Northern Great Plains climate negatively affects stand establishment and persistence. Falcata alfalfa (Medicago sativa subs. Falcata) produces adventitious shoots from roots, improving stress and drought resistance. This study compared production and forage quality for yellow- flowered falcata alfalfa (FAL) to a conventional alfalfa (var. Vernal [MSP]). Plots were established as randomized complete block design with four replications. Each cultivar was seeded in 2019 as a monoculture. In 2020, two harvests were made and sampled. Dry matter yield (DMY) and nutritive value of alfalfa were determined. Results showed first cut DMY was 4,228±361 and 3,442±720 kg/ha for the FAL and MSP, respectively. Results for forage quality for first harvest indicate that FAL alfalfa had greater (P < 0.05) ash (10.36 vs. 9.85 %), lignin (7. 86 vs. 7. 14 %), acid detergent fiber (ADF: 38.4 vs. 33.4%), neutral detergent fiber (NDF: 45.4 vs. 39.0 %) but less crude protein (CP; 18.7 vs. 21.2 %, DM basis), total digestible nutrients (TDN: 59.2 vs. 55.5%), non- fiber carbohydrates (NFC; 186 vs. 164), sugar (8.4 vs. 7.0 %), in vitro true dry matter digestibility after a 48-h incubation (IVTDMD48: 58.6 vs. 55.8%), compared with FAL. However, for the second harvest, DMY was 2,837±361 kg/ha for FAL, which had greater CP (20.4 vs. 19.4%), similar ADF (35.4 vs. 35.0), NDF (42.7 vs. 41.8 %), and IVTDMD48 (65.6 vs. 64.0%), but lower lignin (7.68 vs. 7.84%) and TDN (58.1 vs 58.9%) than MSP which yielded 2546 ±515 kg/ha. Falcata had greater nutritive value at second cutting and greater yield compared with Medicago but generally differed little for quality, suggesting falcata can be a viable alternative legume for Northern Plains.
48
Talsnes, Rune K., Lars Jonatan Engdahl, and Øyvind Sandbakk. "How Do the Effects of an 8-Week Intervention Influence Subsequent Performance Development in Cross-Country Skiers?" International Journal of Sports Physiology and Performance 17, no. 4 (April 1, 2022): 594–604. http://dx.doi.org/10.1123/ijspp.2021-0356.
Повний текст джерелаАнотація:
Purpose: To investigate how the effects of increased low- versus high-intensity endurance training in an 8-week intervention influenced the subsequent development of performance and physiological indices in cross-country skiers. Methods: Forty-four (32 men and 12 women) junior cross-country skiers were randomly assigned into a low-intensity training group (LITG, n = 20) or high-intensity training group (HITG, n = 24) for an 8-week intervention followed by 5 weeks of standardized training with similar intensity distribution, and thereafter 14 weeks of self-chosen training. Performance and physiological indices in running and in roller-ski skating were determined preintervention, after the intervention, and after the standardized training period. Roller-ski skating was also tested after the period of self-chosen training. Results: No between-groups changes from preintervention to after the standardized training period were found in peak speed when incremental running and roller-ski skating (P = .83 and .51), although performance in both modes was improved in the LITG (2.4% [4.6%] and 3.3% [3.3%], P < .05) and in roller-ski skating for HITG (2.6% [3.1%], P < .01). While improvements in maximal oxygen consumption running and peak oxygen uptake roller-ski skating were greater in HITG than in LITG from preintervention to after the intervention, no between-groups differences were found from preintervention to after the standardized training period (P = .50 and .46), although peak oxygen uptake in roller-ski skating significantly improved in HITG (5.7% [7.0%], P < .01). No changes either within or between groups were found after the period of self-chosen training. Conclusions: Differences in adaptations elicited by a short-term intervention focusing on low- versus high-intensity endurance training had little or no effect on the subsequent development of performance or physiological indices following a period of standardized training in cross-country skiers.
49
Guo, Honghai, Ping'an Ding, Peigang Yang, Yuan Tian, Yang Liu, Ze Zhang, Tao Zheng, et al. "Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e16091-e16091. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e16091.
Повний текст джерелаАнотація:
e16091 Background: Neoadjuvant chemotherapies have been widely recommended by clinical guidelines for patients with locally advanced gastric cancer. However, the evidence of combining neoadjuvant chemotherapy with anti-programmed death 1 (anti-PD-1) antibody therapy for patients with locally advanced gastric cancer is inadequate. Thus, we conducted a single-arm phase II trial to evaluate the efficacy and safety of anti-PD-1 antibody sintilimab and XELOX regimen (capecitabine plus oxaliplatin) in patients with locally advanced gastric adenocarcinoma. Methods: Patients with locally advanced(cT3-4 N+ M0, CY0,P0) were enrolled and received four preoperative cycles of XELOX (oxaliplatin 130mg/m2, IV, d1 with capecitabine 1000mg/m2, bid, d1-d14, q21d) and sintilimab (200mg, IV, q21d). Surgery was performed within 3-4 weeks after completion preoperative therapy. After surgery, patients received four cycles of XELOX. The primary endpoint was the pathological complete response (pCR) rate and the secondary endpoints were major pathologic response (MPR) rate, R0 resection rate, safety, disease-free survival (DFS) and overall survival (OS). This clinical trial is registered at ChiCTR.gov.cn: ChiCTR2000030414. Results: From March 2020 to July 2021, 30 patients were enrolled, with median age 62 years (range30-72), males 18, cT3/T4: 8/22, cN1/2/3: 10/14/6, intestinal diffuse type (Lauren classification):17/13, ECOG PS 0/1/2: 19/8/3. There were 19(63.3%) patients with PD-L1 CPS≥1. All patients were available for preoperative response evaluation, the objective response (ORR) rate was 70.0% (95% CI, 50.6%-85.3%) and the disease control (DCR) rate was 100% (95% CI, 88.4%-100%). All (100%) achieved R0 resection. 10 patients (33.3%) achieved pCR (TRG 0) and 19 patients (63.3%) had MPR (TRG 0-1). Common treatment-related adverse events (TRAEs) were anemia (36.7%), leukopenia (36.7%), neutropenia (30.0%), diarrhea (26.6%), ALT increase (23.3%), AST increase (13.3%), thrombocytopenia (10.0%), vomiting (10.0%). The potential immune-related adverse events (irAEs) were dermatitis (6.7%), hypothyroidism (3.3%), pneumonia (10.0%). Most of the TRAEs and potential irAEs were grade 1 or 2. Grade3 TRAEs and irAEs included ALT increase (3.3%), AST increase (3.3%), dermatitis (3.3%). There were no severe complications and death related to the operation. The median postoperative hospital stay was 8 days (range6-23 days). Conclusions: Sintilimab plus XELOX as neoadjuvant therapy showed an encouraging pCR rate, MPR rate and manageable safety. This combination regimen might provide a new option for patients with locally advanced gastric cancer. Clinical trial information: ChiCTR2000030414.
50
Prieto-Peña, D., S. Remuzgo Martinez, F. Genre, V. Pulito-Cueto, B. Atienza-Mateo, B. Sevilla, J. Llorca, et al. "POS0113 BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 267.2–268. http://dx.doi.org/10.1136/annrheumdis-2021-eular.707.
Повний текст джерелаАнотація:
Background:BAFF, APRIL and BAFFR are genes that encode cytokines with a key role in the development and survival of B-lymphocytes [1-4]: The B cell-activating factor (BAFF, also known as BLyS), a proliferation-inducing ligand (APRIL) and BAFF receptor (BAFF-R), respectively. Previous genetic studies have revealed that the BAFF-APRIL-BAFFR pathway is implicated in the genetic predisposition to several immune-mediated diseases [5].Objectives:To determine whether the BAFF-APRIL-BAFFR pathway represents a novel genetic risk factor for the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory disease in which IgA deposits and B-lymphocytes are crucial [6, 7].Methods:A functional BAFF polymorphism (rs374039502) and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients (the largest series of Caucasian patients with IgAV ever assessed for genetic studies) and 806 sex and ethnically matched healthy controls by TaqMan assays.Results:No statistically significant differences in the genotype and allele frequencies between patients with IgAV and healthy controls were observed when each genetic variant of BAFF APRIL and BAFFR was analyzed independently (Table 1). Likewise, no statistically significant differences in genotype and allele frequencies of BAFF APRIL or BAFFR were found when patients with IgAV were stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Similar results were disclosed when haplotype frequencies of APRIL and BAFFR were compared between patients with IgAV and healthy controls as well as patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations.Conclusion:Our results suggest that the BAFF-APRIL-BAFFR pathway does not contribute to the genetic network underlying IgAV.References:[1]J Exp Med 1999;190:1697-710; [2] Science 1999;285:260-3; [3] Nat Genet 2005;37:829-34; [4] Nat Immunol 2002;3:822-9; [5] N Engl J Med 2017;376:1615-26; [6] N Engl J Med 2013;368:2402-14; [7] Autoimmun Rev 2018;17:301-315.Table 1.Genotype and allele frequencies of BAFF, APRIL and BAFFR genes in patients with IgA vasculitis and healthy controls.PolymorphismLocus1/2Data set1/11/22/212rs374039502BAFFT/APatients91.9 (353)8.1 (31)095.9 (737)4.1 (31)Controls91.5 (733)8.1 (65)0.4 (3)95.6 (1531)4.4 (71)rs11552708APRILG/APatients78.1 (299)20.6 (79)1.3 (5)88.4 (677)11.6 (89)Controls77.9 (625)20.4 (1641.6 (13)88.1 (1414)11.9 (190)rs6608APRILC/TPatients71.9 (277)26.0 (100)2.1 (8)84.9 (654)15.1 (116)Controls70.0 (561)27.6 (221)2.5 (20)83.7 (1343)16.3 (261)rs7290134BAFFRA/GPatients58.0 (224)36.3 (140)5.7 (22)76.2 (588)23.8 (184)Controls57.2 (459)36.4 (292)6.5 (52)75.3 (1210)24.6 (396)rs77874543BAFFRG/CPatients82.7 (316)16.0 (61)1.3 (5)90.7 (693)9.3 (71)Controls83.0 (666)16.6 (133)0.4 (3)91.3 (1465)8.7 (139)Acknowledgements:This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CM20/00006]; SR-M is supported by funds of the RETICS Program co-funded by the European Regional Development Fund (ERDF) [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; BA-M is a recipient of a `López Albo´ Post-Residency Programme funded by Servicio Cántabro de Salud; LL-G is supported by funds of IDIVAL [grant number INNVAL20/06]; RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) [grant number CP16/00033].Disclosure of Interests:Diana Prieto-Peña Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Sara Remuzgo Martinez: None declared, Fernanda Genre: None declared, Verónica Pulito-Cueto: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Llorca: None declared, Norberto Ortego: None declared, Leticia Lera-Gómez: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, J. Narváez: None declared, Luis Martín-Penagos: None declared, Jose Alberto Miranda-Filloy: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Javier Sanchez Perez: None declared, Diego de Argila: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galindez: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Miguel A González-Gay Speakers bureau: Pfizer, Abbvie, MSD, Grant/research support from: Pfizer, Abbvie, MSD, Raquel López-Mejías: None declared